AU2022345008A1 - 2-aryl or heteroaryl-3-oxo-4-carbamide-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in the treatment of diseases and disorders - Google Patents
2-aryl or heteroaryl-3-oxo-4-carbamide-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in the treatment of diseases and disorders Download PDFInfo
- Publication number
- AU2022345008A1 AU2022345008A1 AU2022345008A AU2022345008A AU2022345008A1 AU 2022345008 A1 AU2022345008 A1 AU 2022345008A1 AU 2022345008 A AU2022345008 A AU 2022345008A AU 2022345008 A AU2022345008 A AU 2022345008A AU 2022345008 A1 AU2022345008 A1 AU 2022345008A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- salt
- cancer
- alkyl
- cases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 title claims abstract description 62
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 title claims abstract description 62
- 208000037765 diseases and disorders Diseases 0.000 title abstract description 6
- 238000011282 treatment Methods 0.000 title description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 250
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 123
- 201000011510 cancer Diseases 0.000 claims abstract description 90
- 238000000034 method Methods 0.000 claims abstract description 67
- 230000009385 viral infection Effects 0.000 claims abstract description 30
- 208000036142 Viral infection Diseases 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims description 131
- 125000000623 heterocyclic group Chemical group 0.000 claims description 83
- -1 Ci-shaloalkyl Chemical group 0.000 claims description 76
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 50
- 125000001072 heteroaryl group Chemical group 0.000 claims description 46
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 39
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 38
- 125000006413 ring segment Chemical group 0.000 claims description 37
- 201000010099 disease Diseases 0.000 claims description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 229910052757 nitrogen Inorganic materials 0.000 claims description 27
- 125000005843 halogen group Chemical group 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 229910052717 sulfur Inorganic materials 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 16
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 15
- 239000003054 catalyst Substances 0.000 claims description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 13
- 125000001153 fluoro group Chemical group F* 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 206010054261 Flavivirus infection Diseases 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 208000025721 COVID-19 Diseases 0.000 claims description 11
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 10
- 229910052786 argon Inorganic materials 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 9
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 7
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 206010005949 Bone cancer Diseases 0.000 claims description 6
- 208000018084 Bone neoplasm Diseases 0.000 claims description 6
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 6
- 208000024519 eye neoplasm Diseases 0.000 claims description 6
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 6
- 201000010536 head and neck cancer Diseases 0.000 claims description 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
- 239000012038 nucleophile Substances 0.000 claims description 5
- 201000008106 ocular cancer Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims description 4
- 208000001455 Zika Virus Infection Diseases 0.000 claims description 4
- 230000002489 hematologic effect Effects 0.000 claims description 4
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 4
- 230000000926 neurological effect Effects 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims description 4
- 201000011531 vascular cancer Diseases 0.000 claims description 4
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 3
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 3
- 241000315672 SARS coronavirus Species 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 208000035332 Zika virus disease Diseases 0.000 claims description 3
- 208000020329 Zika virus infectious disease Diseases 0.000 claims description 3
- 229960003852 atezolizumab Drugs 0.000 claims description 3
- 229950002916 avelumab Drugs 0.000 claims description 3
- 229940121420 cemiplimab Drugs 0.000 claims description 3
- 229940121432 dostarlimab Drugs 0.000 claims description 3
- 229950009791 durvalumab Drugs 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 125000004432 carbon atom Chemical group C* 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 19
- 239000000543 intermediate Substances 0.000 description 19
- 239000000047 product Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 14
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 13
- 241000711573 Coronaviridae Species 0.000 description 12
- 125000003725 azepanyl group Chemical group 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 125000003003 spiro group Chemical group 0.000 description 11
- 238000003818 flash chromatography Methods 0.000 description 10
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 125000005959 diazepanyl group Chemical group 0.000 description 8
- 238000002953 preparative HPLC Methods 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 125000005960 1,4-diazepanyl group Chemical group 0.000 description 7
- 241000710831 Flavivirus Species 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 206010033128 Ovarian cancer Diseases 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 241001678559 COVID-19 virus Species 0.000 description 6
- 206010008342 Cervix carcinoma Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 6
- 125000002393 azetidinyl group Chemical group 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 201000010881 cervical cancer Diseases 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 208000005017 glioblastoma Diseases 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 125000003566 oxetanyl group Chemical group 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 125000001544 thienyl group Chemical group 0.000 description 6
- 206010044412 transitional cell carcinoma Diseases 0.000 description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 206010003571 Astrocytoma Diseases 0.000 description 5
- 208000007641 Pinealoma Diseases 0.000 description 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 5
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 4
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 4
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 4
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 4
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000000346 nonvolatile oil Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 125000005493 quinolyl group Chemical group 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- NYARTXMDWRAVIX-UHFFFAOYSA-N 2-(4-chlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(Cl)C=C1 NYARTXMDWRAVIX-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 201000009047 Chordoma Diseases 0.000 description 3
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 description 3
- 206010012310 Dengue fever Diseases 0.000 description 3
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 3
- 241000711467 Human coronavirus 229E Species 0.000 description 3
- 241000482741 Human coronavirus NL63 Species 0.000 description 3
- 241001428935 Human coronavirus OC43 Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 3
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 201000005969 Uveal melanoma Diseases 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 201000007455 central nervous system cancer Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 208000025729 dengue disease Diseases 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000002632 imidazolidinyl group Chemical group 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 125000005956 isoquinolyl group Chemical group 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 208000029974 neurofibrosarcoma Diseases 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 208000024724 pineal body neoplasm Diseases 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000001113 thiadiazolyl group Chemical group 0.000 description 3
- 125000001984 thiazolidinyl group Chemical group 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 125000004306 triazinyl group Chemical group 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- LIXNWFSTAHULTE-UHFFFAOYSA-N 3-chloro-6-oxo-1h-pyridazine-5-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=NNC1=O LIXNWFSTAHULTE-UHFFFAOYSA-N 0.000 description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 2
- 102000008142 Cytochrome P-450 CYP1A1 Human genes 0.000 description 2
- 208000001490 Dengue Diseases 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241001109669 Human coronavirus HKU1 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 206010028729 Nasal cavity cancer Diseases 0.000 description 2
- 206010028767 Nasal sinus cancer Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 206010073338 Optic glioma Diseases 0.000 description 2
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000003937 Paranasal Sinus Neoplasms Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 206010057293 West Nile viral infection Diseases 0.000 description 2
- 208000003152 Yellow Fever Diseases 0.000 description 2
- 241000907316 Zika virus Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 125000005418 aryl aryl group Chemical group 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 2
- 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 208000018463 endometrial serous adenocarcinoma Diseases 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 229940102213 injectable suspension Drugs 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 2
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 2
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 208000008511 optic nerve glioma Diseases 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 201000006958 oropharynx cancer Diseases 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 125000005961 oxazepanyl group Chemical group 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 2
- 201000007052 paranasal sinus cancer Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 208000010626 plasma cell neoplasm Diseases 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 238000005956 quaternization reaction Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000023747 urothelial carcinoma Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 206010046885 vaginal cancer Diseases 0.000 description 2
- 208000013139 vaginal neoplasm Diseases 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- VWBPPYBBVMPZOZ-UHFFFAOYSA-N 2-(3-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC(F)=C1 VWBPPYBBVMPZOZ-UHFFFAOYSA-N 0.000 description 1
- BLDFSDCBQJUWFG-UHFFFAOYSA-N 2-(methylamino)-1,2-diphenylethanol Chemical compound C=1C=CC=CC=1C(NC)C(O)C1=CC=CC=C1 BLDFSDCBQJUWFG-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- FRCXPDWDMAYSCE-UHFFFAOYSA-N 3,6-dichloropyridazine-4-carboxylic acid Chemical compound OC(=O)C1=CC(Cl)=NN=C1Cl FRCXPDWDMAYSCE-UHFFFAOYSA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WSHKRAZIHUZWQL-UHFFFAOYSA-N 3-chloro-6-oxo-1h-pyridazine-5-carboxamide Chemical class NC(=O)C1=CC(Cl)=NNC1=O WSHKRAZIHUZWQL-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- ZHCAZQRACAKDHE-UHFFFAOYSA-N 6-oxo-1h-pyridazine-5-carboxamide Chemical class NC(=O)C1=CC=NN=C1O ZHCAZQRACAKDHE-UHFFFAOYSA-N 0.000 description 1
- AZNSKHLQNCKBHC-UHFFFAOYSA-N 6-oxo-1h-pyridazine-5-carboxylic acid Chemical class OC(=O)C1=CC=NN=C1O AZNSKHLQNCKBHC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 101150104892 AHR gene Proteins 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 208000009888 Adrenocortical Adenoma Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 1
- 206010002240 Anaplastic thyroid cancer Diseases 0.000 description 1
- 206010051810 Angiomyolipoma Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010060971 Astrocytoma malignant Diseases 0.000 description 1
- 206010065869 Astrocytoma, low grade Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004992 Bladder adenocarcinoma stage unspecified Diseases 0.000 description 1
- 206010005081 Bladder squamous cell carcinoma stage unspecified Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 101100497948 Caenorhabditis elegans cyn-1 gene Proteins 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 208000037138 Central nervous system embryonal tumor Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009253 Clear cell sarcoma of the kidney Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 201000005171 Cystadenoma Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 201000008228 Ependymoblastoma Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 206010014968 Ependymoma malignant Diseases 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000017259 Extragonadal germ cell tumor Diseases 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 208000005234 Granulosa Cell Tumor Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 101000690540 Homo sapiens Aryl hydrocarbon receptor Proteins 0.000 description 1
- 101000941690 Homo sapiens Cytochrome P450 1A1 Proteins 0.000 description 1
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000035771 Malignant Sertoli-Leydig cell tumor of the ovary Diseases 0.000 description 1
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010070665 Mesoblastic nephroma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010027761 Mixed hepatocellular cholangiocarcinoma Diseases 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 208000003019 Neurofibromatosis 1 Diseases 0.000 description 1
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241001292005 Nidovirales Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 238000010806 PrimeScriptTM RT Reagent kit Methods 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000008938 Rhabdoid tumor Diseases 0.000 description 1
- 206010073334 Rhabdoid tumour Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000001662 Subependymal Glioma Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 201000006449 West Nile encephalitis Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 201000004296 Zika fever Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 208000015234 adrenal cortex adenoma Diseases 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 201000003354 adrenal cortical adenoma Diseases 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000008055 alkyl aryl sulfonates Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 201000006587 bladder adenocarcinoma Diseases 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 201000011281 bladder sarcoma Diseases 0.000 description 1
- 201000006598 bladder squamous cell carcinoma Diseases 0.000 description 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 description 1
- 201000001528 bladder urothelial carcinoma Diseases 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 201000005389 breast carcinoma in situ Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
- 208000030239 cerebral astrocytoma Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 208000030748 clear cell sarcoma of kidney Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 201000010276 collecting duct carcinoma Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 229940125368 controlled substance Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 150000001975 deuterium Chemical class 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 208000014616 embryonal neoplasm Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 208000027858 endometrioid tumor Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 208000032099 esthesioneuroblastoma Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 201000010972 female reproductive endometrioid cancer Diseases 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 208000025750 heavy chain disease Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 201000000284 histiocytoma Diseases 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 102000047528 human AHR Human genes 0.000 description 1
- 102000052268 human CYP1A1 Human genes 0.000 description 1
- 102000047486 human GAPDH Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 201000008893 intraocular retinoblastoma Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 201000000573 juvenile pilocytic astrocytoma Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000024596 kidney oncocytoma Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000011059 lobular neoplasia Diseases 0.000 description 1
- 208000030173 low grade glioma Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000022080 low-grade astrocytoma Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000030883 malignant astrocytoma Diseases 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 201000008203 medulloepithelioma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 201000004058 mixed glioma Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000012221 ovarian Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 201000011144 pancreatic adenosquamous carcinoma Diseases 0.000 description 1
- 230000009996 pancreatic endocrine effect Effects 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 201000009612 pediatric lymphoma Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000005039 renal oncocytoma Diseases 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 208000030819 subependymoma Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 229940042055 systemic antimycotics triazole derivative Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- FERKWUXUTFCIFW-UHFFFAOYSA-N trimethyl-[2-[[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]methoxy]ethyl]silane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(COCC[Si](C)(C)C)N=C1 FERKWUXUTFCIFW-UHFFFAOYSA-N 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 208000012498 virus associated tumor Diseases 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Disclosed herein are compounds which can act modulators of the aryl hydrocarbon receptor (AHR). Further disclosed herein are methods for treating diseases and disorders, such as cancer and viral infections, using the compounds disclosed herein.
Description
2-ARYL OR HETEROARYL-3-OXO-4-CARBAMIDE-6-CYCLIC-DIHYDROPYRAZINE ARYL HYDROCARBON RECEPTOR MODULATORS AND THEIR USE IN THE TREATMENT OF DISEASES AND DISORDERS
Field of the Invention
[0001] This disclosure relates to compounds that are useful as aryl hydrocarbon receptor (AHR) activity modulators, pharmaceutical formulations thereof, and methods of using the compounds to treat diseases and disorders, such as cancer.
Description of Related Technology
[0002] The aryl hydrocarbon receptor (AHR) is a ligand-dependent transcription factor that regulates gene expression in a variety of cells, such as epithelial and immune cells. Emerging evidence suggests that AHR plays a role in the initiation, promotion, progression, invasion, and metastasis of cancer cells. Various tumor types and tumor cell lines show high AHR expression, suggesting that AHR is activated in tumors and facilitates their growth. Immune evasion is gaining recognition as a hallmark feature of cancer. A connection between the AHR and immune system has been identified, and AHR has been suggested as an immunosuppressive effector on different types of immune cells. Certain cancers can escape immune recognition via AHR signaling pathways. Overall, modulating AHR activity in cancer cells, immune cells, stromal cells, fibroblasts, and endothelial cells within a tumor can slowdown the progression of the disease
[0003] AHR is expressed at high levels and is chronically active in blood tumors, such as T-cell leukemia and lymphoma, as well as in solid tumors, such as glioblastoma, ovarian cancer, lung cancer, liver cancer, and head and neck carcinomas. It has been suggested that detection of AHR activity in the tumor microenvironment can serve as a potent diagnostic indicator for tumor aggressiveness. Depending on the cancer type, two types of results are associated with AHR activity and the prognosis. There is evidence that, in hormone-dependent breast cancers, AHR activation is associated with attenuated aggressiveness and a better prognosis. In contrast, higher AHR activity has been suggested as being correlated with increased aggressiveness and a poor prognosis in non-small-cell lung cancer.
[0004] Recent reports have also demonstrated the role of AHR as a modulator of the intrinsic, innate and adaptive immune response to viral infections. The role of AHR activation has been recognized as influencing host resistance to infections by a variety of viruses, including influenza, coronaviruses (such as SARS-CoV-1, SARS-CoV-2, and MERS-CoV), flaviviruses (such as Zika virus), retroviruses (such as HIV), and herpesviruses.
[0005] As such, there is a need for novel compounds that modulate AHR activity to provide new and effective therapies for diseases and disorders, such as cancer and viral infections.
SUMMARY
[0006] One aspect of the disclosure provides a compound, or pharmaceutically acceptable salt thereof, having
a structure of Formula (I):
(|), wherein each RN is independently H or C1-6alkyl; R1 is H, C1-6alkyl, C1-6alkylene-NRNRN, C1-6alkylene-O-C1-6alkyl, C1-6alkylene-C(O)R2, C1-6alkylene-NRN-C(O)-C1-3alkyl, C3. 8cycloalkyl, or 4-12 membered heterocyclyl, wherein 1-3 ring atoms are selected from 0, N, and S, and the cycloalkyl or heterocyclyl is optionally substituted with 1 or 2 Ci-salkyl, C(0)-C1-6alkyl, and =0; R2 is OH, O-Ci. ealkyl, or NRNRN; Ar1 is C6-10aryl or 5-10 membered heteroaryl, wherein 1-3 ring atoms are selected from 0, N, and S, and Ar1 is optionally substituted with 1 or 2 R3; each R3 is independently halo, Ci ealkyl, Ci ehaloalkyl, or C3-6cycloalkyl; Ar2 is C5-8cycloakly, C5-8cycloalkenyl, C6-10aryl, or 5-12 membered heterocyclyl or heteroaryl, wherein 1-3 ring atoms are selected from 0, N, and S, and Ar2 is optionally substituted with 1, 2, or 3 R4; each R4 is independently halo, OH, =0, ON, C1-6alkyl, C1-6haloalkyl, C1-6hydroxyalkyl, C1-6alkoxy, Ci-shaloalkoxy, NRNRN, C0NRNRN, COOH, C00-C1-6alkyl, C(0)-Ci.6alkyl, SO2-Ci.6alkyl, C3-8cycloalkyl, 4-12 membered heterocyclyl or 5- 12 membered heteroaryl, wherein 1-3 ring atoms are selected from 0, N, and S, or phenyl, and the heterocyclyl, heteroaryl, or phenyl is substituted with 0, 1, or 2 substituents independently selected from halo and C1-6alkyl, or R1 can be C2-6hydroxyalkyl when Ar2 is (1) C5-8cycloakly, C5-8cycloalkenyl, C10aryl, 4-12-membered heterocyclyl, or 5- or 7-12 membered heteroaryl and Ar2 is optionally substituted with 1, 2, or 3 R4; or (2) phenyl or 6- membered heteroaryl and Ar2 is substituted with at least one R4 selected from C0NRNRN, COOH, COO-C1-6alkyl, C(0)-C1-6alkyl, SO2-C1-6alkyl, C3-8cycloalkyl, 4-12 membered heterocyclyl, 5-12 membered heteroaryl, and phenyl, and the phenyl, heterocyclyl or heteroaryl is substituted with 0, 1, or 2 substituents independently selected from halo and C1-6alkyl.
[0007] In some cases, each RN is independently H or methyl. In some cases, R1 is H or C1-6alkyl. In some cases, R1 is methyl. In some cases, R1 is C1-6alkylene-NRNRN or C1-6alkylene-O-C1-6alkyl. In some cases, R1 is
6alkylene-C(O)R2 or C1-6alkylene-NRN-C(O)CH3. In some cases, R2 is OH. In some cases, R2 is N H2, NHCH3, or N(CH3)2. In some
cases, R1 is heterocyclyl comprising 4-12 total ring atoms, wherein 1-3 of the ring atoms are selected from 0, N,
and S. In some cases, the heterocyclyl is unsubstituted. In some cases, the heterocyclyl is substituted with 1 or
[0008] In some cases, Ar1 is Ce-waryl. In some cases, Ar1 is phenyl. In some cases, Ar1 is 5-10 membered heteroaryl. In some cases, Ar1 is unsubstituted. In some cases, Ar1 is
, In some cases, Ar1 is substituted with 1 or 2 R3. In some cases, R3 is fluoro, chloro, methyl, ethyl, isopropyl, cyclopropyl, or trifluromethyl. In some cases, Ar1 is
,
[0009] In some cases, Ar2 is Ce-waryl. In some cases, Ar2 is phenyl. In some cases, Ar2 is 5-12 membered heteroaryl. In some cases, Ar2 is C5-8cycloalkyl, C5-8cycloalkenyl, or 5-12 membered heterocyclyl. In some cases, Ar2 is unsubstituted. In some cases, Ar2 is substituted with 1 , 2, or 3 R4. In some cases, Ar2 is substituted with 1 or 2 R4. In some cases, at least one R4 is halo. In some cases, at least one R4 is chloro In some cases,
In some cases, at least one R4 is fluoro, chloro, OH, ON, CH3, OCH3, CF3, OCF3, CHF2,
CH2F, OCHF2, NH2, N(CH3)2, CONH2, COOH, SO2CH3, cyclopropyl, or morpholino. In some cases, at least one R4 selected from CONRNRN, COOH, COO-C1-6alkyl, C(O)-C1-6alkyl, SO2-C1-6alkyl, C3-8cycloalkyl, 4-12 membered heterocyclyl, 5-12 membered heteroaryl, and phenyl, and the phenyl, heterocyclyl or heteroaryl is substituted with 0, 1, or 2 substituents independently selected from halo and C1-6alkyl. In some cases, Ar2 is phenyl, pyridyl,
pyrimidinyl, pyrazolyl, or triazolyl, and at least one R4 is phenyl or halo substituted-phenyl.
[0011] In another aspect, the disclosure provides a compound as listed in Table 1, or a pharmaceutically acceptable salt thereof.
[0012] In a further aspect, the disclosure provides a pharmaceutical formulation comprising the compound or salt of the disclosure (e.g., compounds of Formula (I), Table 1, and salts thereof) and a pharmaceutically acceptable excipient.
[0013] Yet another aspect of the disclosure provides a method for modulating aryl hydrocarbon receptor (AHR) activity in a subject, comprising contacting the AHR with a compound or salt of the disclosure (e.g., compounds of Formula (I), Table 1 , and salts thereof) or a pharmaceutical composition thereof, as disclosed herein.
[0014] Another aspect of the disclosure provides a method for treating or preventing a disease or disorder in a subject, comprising administering to the subject a therapeutically effective amount of a compound or salt of the disclosure (e.g., compounds of Formula (I), Table 1 , and salts thereof), or the pharmaceutical composition thereof, as disclosed herein. In some cases, the disease or disorder is cancer, a viral infection, or pulmonary
arterial hypertension (PAH). In some cases, the viral infection is flavivirus infection or coronavirus infection In some cases, the viral infection is flavivirus infection. In some cases, the flavivirus infection is Zika virus infection. In some cases, the viral infection is coronavirus infection. In some cases, the coronavirus infection is severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), or Coronavirus disease 2019 (COVID-19). In some cases, the coronavirus infection is Coronavirus disease 2019 (COVID-19). In some cases, the disease or disorder is cancer. In some cases, the cancer is a liquid or solid tumor, hematological cancer, lymphoma, myeloma, leukemia, sarcoma, eye cancer, thyroid cancer, parathyroid cancer, neurological cancer, skin cancer, breast cancer, uterine cancer, endometrial cancer, prostate cancer, colorectal cancer, lung cancer, head and neck cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, genitourinary cancer, bone cancer, renal cancer, or vascular cancer. In some cases, the method further comprises administration of a therapeutic agent. In some cases, the therapeutic agent is an immune checkpoint inhibitor. In some cases, the immune checkpoint is PD1 or PDL1 . In some cases, the immune checkpoint inhibitor is pembrolizumab, nivolumad, cemiplimab, atezolizumab, dostarlimab, durvalumab, avelumab, or a combination thereof.
[0015] Another aspect of the disclosure relates to use of a compound or salt disclosed herein (e.g., compounds of Formula (I), Table 1 , and salts thereof), or a pharmaceutical composition disclosed herein for modulating AHR activity in a subject. A further aspect of the disclosure relates to use of a compound disclosed herein (e.g., compounds of Formula (I), Table 1 , and salts thereof), or a pharmaceutical composition disclosed herein for treating or preventing a disease or disorder in a subject.
[0016] Further provided are compounds of Formula (A) or (B):
wherein Ar1 is Ce -ioaryl or 5-10 membered heteroaryl, wherein 1-3 ring atoms are selected from 0, N, and S, and Ar1 is optionally substituted with 1 or 2 R3; each R3 is independently halo, C1-6alkyl, C1-6haloalkyl, or C3. ecycloalkyl; R1 is H, C1-6alkyl, Ci.ealkylene-NRNRN, C1-6alkylene-O-C1-6alkyl, Ci.ealkylene-C(O)R2, C1-6alkylene- NRN-C(O)-C1-3alkyl, Cg-scycloalkyl, or 4-12 membered heterocyclyl, wherein 1-3 ring atoms are selected from 0, N, and S, and the cycloalkyl or heterocyclyl is optionally substituted with 1 or 2 C1-6alkyl, C(O)-C1-6alkyl, and =0; R2 is OH, O-C1-6alkyl, or NRNRN; each RN is independently H or C1-6alkyl; X is a leaving group; and R is H, Ci- ealkyl, or phenyl. In some cases, X is chloro, fluoro, mesyl, tosyl, or triflyl.
[0017] Also provided are methods of preparing a compound or salt of Formula (I) comprising admixing a compound of Formula (B) as disclosed herein with Ar2-boronic acid or Ar2-boronic ester in the presence of a catalyst to form the compound of Formula (I). Further provides are methods of preparing a compound or salt of Formula (I), comprising admixing a compound of Formula (A) with Ar2-boronic acid or Ar2-boronic ester in the presence of a catalyst to form an intermediate then converting the -OR moiety of the intermediate to a -N(RN)R1 moiety to form the compound of Formula (I). In various cases, the catalyst comprises a palladium catalyst. Also
provided are methods of preparing the compound or salt of Formula (I), comprising admixing the compound of Formula (B) with an amine nucleophile, optionally in the presence of a catalyst, to form an aromatic intermediate, then reacting the aromatic intermediate with a reagent to form the compound of Formula (I). Further provided are methods of preparing the compound or salt of Formula (I), comprising (i) admixing the compound of Formula (A) with an amine nucleophile, optionally in the presence of a catalyst, to form an aromatic intermediate, (ii) reacting the aromatic intermediate with a reagent to form an ester intermediate, and (iii) converting the -OR moiety of the ester intermediate to a -N(RN)R1 moiety to form the compound of Formula (I).
[0018] Further aspects and advantages will be apparent to those of ordinary skill in the art from a review of the following detailed description, taken in conjunction with the drawings While the compounds and methods disclosed herein are susceptible of embodiments in various forms, the description hereafter includes specific embodiments with the understanding that the disclosure is illustrative, and is not intended to limit the invention to the specific embodiments described herein.
BRIEF DESCRIPTIONS OF THE FIGURES
[0019] Figure 1 shows tumor volume over time of mice having CT26 tumor cells dosed with (a) vehicle; (b) anti-PD1 antibody; (c) Compound Example 184; or (d) combination of Compound Example 184 and anti-PD1 antibody.
[0020] Figure 2 shows the survival of mice having CT26 tumor cells and dosed with (a) vehicle; (b) anti-PD1 antibody; (c) Compound Example 184; or (d) combination of Compound Example 184 and anti-PD1 antibody.
DETAILED DESCRIPTION
[0021] Provided herein are compounds of Formula (
I) wherein Ar1, Ar2, R1, and RN are as described herein, which can function as modulators of AHR activity. For example, the compounds can increase or decrease AHR activity.
[0022] The compounds disclosed herein are useful for targeting and selectively inhibiting AHR. It has been found that multiple tumor types have high levels of AHR signaling as determined by an AHR-gene signature. The high level of AHR activation caused by elevated levels of kynurenine and other ligands, as well as its role in driving an immune suppressive tumor microenvironment (TME), make AHR an attractive therapeutic target in multiple cancer types.
[0023] Many viral infections have also been found to involve AHR signaling. AHR is implicated in regulating the immune response, and AHR activation has been associated with adaptive immune response impairment and poor health outcomes in a variety of viral infections (e.g., influenza). Inhibition of AHR has also been associated with diminished production of viral particles in vivo (e.g., Dengue fever). AHR appears to play a role in controlling
lipid biogenesis, a hallmark of Hepatitis C (HCV) infection. The role of AHR in the regulation of the host immune response against many viruses, such as the examples given above, make modulation of AHR an attractive therapeutic target for viral infections
[0024] AHR modulation has also been implicated in treating pulmonary arterial hypertension (PAH).
[0025] Accordingly, in some cases, the present disclosure provides compounds useful for treating a disease or disorder, e.g., cancer, a viral infection, or PAH, in a subject. Also provided are methods of treating a disease or disorder, e.g., cancer, a viral infection, or PAH, in a subject, comprising administering to the subject a therapeutically effective amount of a compound disclosed herein, e.g., a compound of Formula (I) or Table 1, or a pharmaceutically acceptable salt thereof. Further provided are pharmaceutical compositions comprising a compound disclosed herein, e.g., a compound of Formula (I) or Table 1, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions in methods of treating a disease or disorder, e.g., cancer, a viral infection, or PAH.
Compounds of the Disclosure
[0026] In one aspect, disclosed herein are compounds having a structure of Formula (I):
wherein each RN is independently H or C1-6alkyl;
R1 is H, C1-6alkyl, C1-6alkylene-NRNRN, C1-6alkylene-O-C1-6alkyl, C1-6alkylene-C(O)R2, C1-6alkylene-NRN-C(O)-C1-3alkyl, C3-8cycloalkyl, or 4-12 membered heterocyclyl, wherein 1-3 ring atoms are selected from O, N, and S, and the cycloalkyl or heterocyclyl is optionally substituted with 1 or 2 C1-6alkyl, C(O)- C1-6alkyl, and =0;
R2 is OH, O-Ci-salkyl, or NRNRN;
Ar1 is Ce-waryl or 5-10 membered heteroaryl, wherein 1-3 ring atoms are selected from 0, N, and S, and Ar1 is optionally substituted with 1 or 2 R3; each R3 is independently halo, C1-6alkyl, C1-6haloalkyl, or Cs-ecycloalkyl;
Ar2 is C5-8cycloakly, C5-8cycloalkenyl, Ce-waryl, or 5-12 membered heterocyclyl or heteroaryl, wherein 1- 3 ring atoms are selected from 0, N, and S, and Ar2 is optionally substituted with 1 , 2, or 3 R4; each R4 is independently halo, OH, =0, ON, C1-6alkyl, C1-6haloalkyl, C1-6hydroxyalkyl, Cvealkoxy, Ci- ehaloalkoxy, NRNRN, C0NRNRN, COOH, COO-Ci.6alkyl, C(O)-Ci.6alkyl, S02-Ci.6alkyl, C3.ecycloalkyl, 4-12 membered heterocyclyl or 5-12 membered heteroaryl, wherein 1-3 ring atoms are selected from 0, N, and S, or phenyl, and the heterocyclyl, heteroaryl, or phenyl is substituted with 0, 1 , or 2 substituents independently selected from halo and C1-6alkyl,
or R1 can be C^ehydroxyalkyl when Ar2 is (1) C5-8cycloakly, C5-8cycloalkenyl, Cioaryl, 4-12- membered heterocyclyl, or 5- or 7-12 membered heteroaryl and Ar2 is optionally substituted with 1 , 2, or 3 R4; or (2) phenyl or 6-membered heteroaryl and Ar2 is substituted with at least one R4 selected from CONRNRN, COOH, COO-C1-6alkyl, C(O)-Ci.ealkyl, SO2-C1-6alkyl, C3-8cycloalkyl, 4-12 membered heterocyclyl, 5-12 membered heteroaryl, and phenyl, and the phenyl, heterocyclyl or heteroaryl is substituted with 0, 1, or 2 substituents independently selected from halo and C1-6alkyl.
[0027] In some cases, RN is H. In some cases, RN is Ci ealkyl. In some cases, RN is methyl.
[0028] In some cases, R1 is H. In some cases, R1 is C1-6alkyl. In some cases, R1 is methyl, ethyl, propyl, or isopropyl. In some cases, R1 is methyl.
[0029] In some cases, R1 is C1-6alkylene-NRNRN or C1-6alky lene-O-C1-6alkyl . In some cases, R1 is Ci.
6alkylene-NRNRN. In some cases, R1 is C2-3alkylene-NRNRN. In some cases, R1 is C2alkylene-NRNRN. In some cases, R1 is C3alkylene-NRNRN. In some cases, each RN independently is H or CH3. In some cases, each RN is H. In some cases, each RN is CH3. In some cases, one RN is H and one RN is CH3. In some cases, R1 is
. In some cases, R1 is C1-6alkylene-O-C1-6alkyl. In some cases, R1 is C2-3alkylene-O-Cialkyl. In some cases, R1 is
C2alkylene-O-Cialkyl. In some cases, R1 is Csalkylene-O-Cialkyl. In some cases, R1 is
or
. In some cases, R1 is
[0030] In some cases, R1 is H, C^alkyl, C1-6alkylene-NRNRN, C1-6alkylene-O-C1-6alkyl, C1-6alkylene-C(O)R2, C1-6alkylene-NRN-C(O)-C1-3alkyl, or heterocyclyl comprising 4-12 total ring atoms, wherein 1-3 of the ring atoms are selected from O, N, and S and the heterocyclyl is optionally substituted with 1 or 2 C1-6alkyl, C(O)-C1-6alkyl, or =0. In some cases, R1 is C1-6alkylene-C(O)R2 or C1-6alkylene-NRN-C(O)-C1-3alkyl. In some cases, R1 is C1- 6alkylene-C(O)R2 or C1-6alkylene-NRN-C(O)-CH3. In some cases, R1 is C2-3alkylene-C(O)R2 or C2-3alkylene-NRN- C(0)-C1-3alkyl. In some cases, R1 is C2-3alkylene-C(O)R2 or C2-3alkylene-NRN-C(O)-CH3. In some cases, R1 is C1-6alkylene-NRN-C(O)-C1-3alkyl. In some cases, R1 is C2-3alkylene-NRN-C(O)-C1-3alkyl. In some cases, R1 is C2alkylene-NRN-C(O)-C1-3alkyl . In some cases, R1 is C3alkylene-NRN-C(O)-Ci 3alkyl In some cases, R1 is Ci- ealkylene-NRN-C(O)-CH3. In some cases, R1 is C2-3alkylene-NRN-C(O)-CH3. In some cases, R1 is C2alkylene- NRN-C(O)-CH3. In some cases, R1 is C3alkylene-NRN-C(O)-CH3. In some cases, R1 is Ci.ealkylene-C(O)R2. In some cases, R1 is Ci.3alkylene-C(O)R2. In some cases, R1 is Cialkylene-C(O)R2. In some cases, R1 is C2alkylene-C(O)R2. In some cases, R1 is C3alkylene-C(O)R2. In some cases, R2 is OH. In some cases, R2 is 0- C1-6alkyl. In some cases, R2 is O-CH3. In some cases, RN is H. In some cases, RN is CH3. In some cases, R2 is NRNRN. In some cases, R2 is NH2. In some cases, R2 is NHCH3. In some cases, R2 is N(CH3)2. In some cases,
[0031] In some cases, In some cases, R1 is C3-8cycloal kyl optionally substituted with 1 or 2 C1-6alkyl, C(0)-C1- 6alkyl, or =0. In some cases, R1 is unsubstituted C3-8cycloalkyl. In some cases, R1 is C3-8cycloalkyl substituted with 1 or 2 C1-6alkyl, C(O)-C1-6alkyl, or =0. In some cases, R1 is C3-8cycloalky I substituted with 1 or 2 =0. In some cases, R1 is C3-8cycloal kyl substituted with 1 =0. In some cases,
some cases, R1 is
[0032] In some cases, R1 is heterocyclyl comprising 4-12 total ring atoms, wherein 1-3 of the ring atoms are selected from 0, N, and S and the heterocyclyl is optionally substituted with 1 or 2 C1-6alkyl, C(O)-C1-6alkyl, or =0. In some cases, R1 is heterocyclyl comprising 4-7 total ring atoms. In some cases, R1 is heterocyclyl comprising 4 total ring atoms. In some cases, R1 is heterocyclyl comprising 5 total ring atoms. In some cases, R1 is heterocyclyl comprising 6 total ring atoms. In some cases, R1 is heterocyclyl comprising 7 total ring atoms. In some cases, heterocyclyl is oxetanyl, azetidinyl, diazepanyl (such as 1 ,4-diazepanyl), azepanyl, piperidinyl (such as 1 -piperidinyl, 2-piperidinyl, 3-piperidinyl, or 4-piperidinyl), pyrrolidinyl (such as 1-pyrrolidinyl, 2- pyrrolidinyl, or 3-pyrrolidinyl), piperazinyl, pyrazolidinyl, imidazolidinyl, triazepanyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, oxazepanyl, thiazepanyl, tetrahydrofuranyl, tetrahydrothiophenyl, morpholino (such as 3-morpholino or 4-morphol ino), thiomorpholino (such as 2-thiomorphol ino, 3-thiomorpholi no or 4- thiomorpholino), pyrrolidin-2-one, tetrahydropiperazinyl (such as 1-tetrahydropiperazinyl, 2-tetrahydropiperazinyl, or 3-tetrahydropiperazinyl), pyrazolinyl (such as 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, or 5-pyrazolinyl), thiazolidinyl (such as 2-thiazolidinyl, 3-thiazolidinyl, or 4-thiazolidinyl), imidazolidinyl (such as 1 -imidazolidinyl, 2- imidazolidinyl, 4-imidazolidinyl, or 5-imidazolidinyl), or 1,3-dihydro-imidazol-2-only. In some cases, heterocyclyl is oxetanyl, azetidinyl, diazepanyl (such as 1,4-diazepanyl), azepanyl, piperidinyl (such as 1 -piperidinyl, 2- piperidinyl, 3-piperidinyl, or 4-piperidinyl), or pyrrolidinyl (such as 1-pyrrolidinyl, 2-pyrrolidinyl, or 3-pyrrolidinyl). In some cases, heterocyclyl is oxetanyl, azetidinyl, diazepanyl or azepanyl. In some cases, heterocyclyl is diazepanyl or azepanyl. In some cases, heterocyclyl is 1 ,4-diazepanyl or azepanyl In some cases, heterocyclyl is 1,4-diazepanyl. In some cases, heterocyclyl is azepanyl. In some cases, R1 is unsubstituted heterocyclyl. In some cases, R1 is heterocyclyl substituted with 1 or 2 C1-6alkyl, C(O)-C1-6alkyl, or =0. In some cases, R1 is heterocyclyl substituted with 1 C-i-salkyl, C(O)-C1-6alkyl, or =0. In some cases, R1 is heterocyclyl substituted with
2 C1-6alkyl, C(O)-C1-6alkyl, or =0 In some cases, R1 is heterocyclyl substituted with C1-6alkyl. In some cases, R1 is heterocyclyl substituted with C(0)-C1-6alkyl. In some cases, R1 is heterocyclyl substituted with =0. In some
some cases, R1 is
In some cases, R1 is
O
In some cases, R1 is
In some cases, R1 is
In some cases, R1 is
. In some cases, R1 is C2-6alkylene-C(O)-NRNRN. In some cases, R1 is
In some cases, R1 is C2- ehydroxyalkyl. In some cases, R1 is
[0033] In some cases, Ar1 is C6-10aryl or 5-10 membered heteroaryl, wherein 1-3 ring atoms are selected from O, N, and S, and Ar1 is optionally substituted with 1 or 2 R3. In some cases, Ar1 is C6aryl or 5-6 membered heteroaryl, and Ar2 is optionally substituted with 1 or 2 R3. In some cases, Ar1 is C6-10aryl. In some cases, Ar1 is phenyl or naphthyl. In some cases, Ar1 is phenyl. In some cases, Ar1 is 5-10 membered heteroaryl . In some cases, Ar1 is 5-6 membered heteroaryl. In some cases, Ar1 is 5-membered heteroaryl. In some cases, Ar1 is 6- membered heteroaryl. In some cases, Ar1 is pyrazolyl, thienyl, furyl, pyridyl, pyrrolyl, oxazolyl, quinolyl, thiophenyl, isoquinolyl, indolyl, triazinyl, triazolyl, isothiazolyl, isoxazolyl, imidazolyl, benzothiazolyl, pyrazinyl, pyrimidinyl, thiazolyl, or thiadiazolyl, and is optionally substituted with 1 or 2 R3. In some cases, Ar1 is pyrazolyl, and is optionally substituted with 1 or 2 R3. In some cases, Ar1 is unsubstituted. In some cases, Ar1 is substituted with 1 or 2 R3. In some cases, Ar1 is substituted with 1 R3. In some cases, Ar1 is substituted with 2 R3. In some cases, at least one R3 is halo. In some cases, each R3 is halo. In some cases, at least one R3 is C1-6alkyl. In some cases, each R3 is C1-6alkyl. In some cases, each R3 independently is fluoro or methyl. In some cases, each R3 is fluoro. In some cases, each R3 is methyl. In some cases, R3 is fluoro, chloro, methyl, ethyl, isopropyl, cyclopropyl, or trifluromethyl. In some cases, Ar1 is
In some cases, Ar1 is
[0034] In some cases, Ar2 is C6-10aryl or 5-12 membered heteroaryl, wherein 1-3 ring atoms are selected from 0, N, and S, and Ar2 is optionally substituted with 1 , 2, or 3 R4. In some cases, Ar2 is C6aryl or 5-6 membered heteroaryl, and Ar2 is optionally substituted with 1 or 2 R4. In some cases, Ar2 is C6-10aryl. In some cases, Ar2 is phenyl or naphthyl. In some cases, Ar2 is phenyl. In some cases, Ar2 is 5-12 membered heterocyclyl and is optionally substituted with 1, 2, or 3 R4. In some cases, Ar2 is 5-12 membered heteroaryl. In some cases, Ar2 is 5-6 membered heteroaryl. In some cases, Ar2 is 5-membered heteroaryl. In some cases, Ar2 is 6-membered heteroaryl. In some cases, Ar2 is piperindinyl, piperazinyl, pyrazolyl, thienyl, furyl, pyridyl, pyrrolyl, oxazolyl, quinolyl, thiophenyl, isoquinolyl, indolyl, triazinyl, triazolyl, isothiazolyl, isoxazolyl, imidazolyl, benzothiazolyl, pyrazinyl, pyrimidinyl, thiazolyl, or thiadiazolyl, and is substituted with 0, 1, or 2 R4. In some cases, Ar2 is pyrazolyl, and is substituted with 0, 1 , or 2 R4. In some cases, Ar2 is unsubstituted. In some cases, Ar2 is substituted with 1 , 2, or 3 R4 (e.g., 1 or 2 R4). In some cases, Ar2 is substituted with 1 R4. In some cases, Ar2 is substituted with 2 R4. In some cases, at least one R4 is halo. In some cases, at least one R4 is OH. In some cases, at least one R4 is CN. In some cases, at least one R4 is C1-6alkyl. In some cases, at least one R4 is methyl, ethyl, propyl, or isopropyl. In some cases, at least one R4 is methyl. In some cases, at least one R4 is Ci ehaloalkyl . In some cases, at least one R4 is CF3 or CHF2, or CH2F. In some cases, at least one R4 is Ci. ehydroxyalkyl. In some cases, at least one R4 is C1-6alkoxy. In some cases, at least one R4 is OCH3. In some cases, at least one R4 is C1-6haloalkoxy. In some cases, at least one R4 is OCF3 or OCHF2. In some cases, at least one R4 is NRNRN. In some cases, at least one R4 is NH2, NHCH3, or N(CH3)2. In some cases, at least one R4 is NH2 or N(CHS)2. In some cases, at least one R4 is CONRNRN. In some cases, at least one R4 is CON(CH3)2, CONHCH3, or CONH2. In some cases, at least one R4 is N(CH3)2, NHCH3, or CONH2. In some cases, at least one R4 is COOH. In some cases, at least one R4 is COO-C1-6alkyl. In some cases, at least one R4 is C(O)-C1-6alkyl. In some cases, at least one R4 is COCH3. In some cases, at least one R4 is SO2-C1-6alkyl. In some cases, at least one R4 is SO2CH3. In some cases, at least one R4 is C3-8cycloalky I. In some cases, at least one R4 comprises cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some cases, at least one R4 comprises cyclopropyl. In some cases, at least one R4 is 4-12 membered heterocyclyl. In some cases, at least one R4 comprises morpholino. In some cases, at least one R4 is fluoro, chloro, OH, ON, CH3, OCH3, CF3, OCF3, CHF2, CH2F, OCHF2, NH2, N(CH3)2, CONH2, COOH, SO2CH3, cyclopropyl, or morpholino. In some cases, at least one R4 is fluoro or chloro. In some cases, at least one R4 is fluoro. In some cases, at least one R4 is chloro. In some cases, each R4 is halo. In some cases, each R4independently is Cl or F. In some cases, each R4 is OH. In some cases, each R4 is ON. In some cases, each R4 is C1-6haloalkyl. In some cases, each R4 is Ci-
6hydroxyalkyl. In some cases, each R4 is C1-6alkoxy . In some cases, each R4 is C1-6haloalkoxy. In some cases, each R4 is NRNRN In some cases, each R4 is CON RNRN. In some cases, each R4 is COOH. In some cases, each R4 is COO-C1-6alky I. In some cases, each R4 is C(O)-C1-6alkyl. In some cases, each R4 is SO2- C1-6alkyl. In some cases, each R4 is C3-8cycloalky I. In some cases, each R4 is 4-12 membered heterocyclyl . In some cases, at least one R4 selected from CONRNRN, COOH, COO-C1-6alkyl, C(O)- C1-6alkyl, S02-C1-6alkyl, C3-8cycloalkyl, 4- 12 membered heterocyclyl, 5-12 membered heteroaryl, and phenyl, and the phenyl, heterocyclyl or heteroaryl is substituted with 0, 1 , or 2 substituents independently selected from halo and C1-6alkyl. In some cases, Ar2 is phenyl, pyridyl, pyrimidinyl, pyrazolyl, or triazolyl, and at least one R4 is phenyl or halo substituted-phenyl.
[0035] In cases where Ar2 is substituted by 1 , 2, or 3 R4, the R4 can be at any position on the ring In some cases, Ar2 is phenyl substituted by 1 or 2 R4 at any position on the ring. In some cases, Ar2 is
some cases, Ar2 is
and R4 is fluoro, chloro, OH, CN, CH3, CH2CH3, CH(CH3)2, C(CH3)3, OCH3, CF3,
OCF3, CHF2, CH2F, OCHF2, NH2, N(CH3)2, CONH2, COOH, SO2CH3, cyclopropyl, or morpholino. In some cases,
In some cases, Ar2 is
and each R4 is independently fluoro, chloro, OH,
CN, CH3, CH2CH3, CH(CH3)2, C(CH3)3, OCH3, CF3, OCF3, CHF2, CH2F, OCHF2, NH2, N(CH3)2, CONH2, COOH,
[0036] Contemplated compounds of Formula (I) include, but are not limited to the compounds listed in Table 1.
Table 1.
[0037] Unless otherwise indicated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, cis-trans, conformational, and rotational) forms of the structure. For example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers are included in this disclosure, unless only one of the isomers is specifically indicated. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, cis/trans, conformational, and rotational mixtures of the present compounds are within the scope of the disclosure. In some cases, the compounds disclosed herein are stereoisomers. "Stereoisomers" refer to compounds that differ in the chirality of one or more stereocenters. Stereoisomers include enantiomers and diastereomers. The compounds disclosed herein can exist as a single stereoisomer, or as a mixture of stereoisomers. Stereochemistry of the compounds shown herein indicate a relative stereochemistry, not absolute, unless discussed otherwise. As indicated herein, a single stereoisomer, diastereomer, or enantiomer refers to a compound that is at least more than 50% of the indicated stereoisomer, diastereomer, or enantiomer, and in some cases, at least 90% or 95% of the indicated stereoisomer, diastereomer, or enantiomer.
[0038] The compounds of Formula (I) can have any stereochemical configuration at the sp3 carbon atoms. In some cases, the compounds of the disclosure are optically pure. As used herein, “optically pure” refers to the presence of only one enantiomer of a compound if multiple stereochemical configurations can exist. In various cases, the chiral moieties present in the compounds of the disclosure are derived from either natural or unnatural amino acids or saccharides.
[0039] Unless otherwise indicated, all tautomeric forms of the compounds of the disclosure are within the scope of the disclosure.
[0040] Additionally, unless otherwise indicated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13C- or MC-enriched carbon are within the scope of this disclosure. Such compounds are useful, for example, as analytical tools or probes in biological assays. Such compounds, especially deuterium analogs, can also be therapeutically useful. Thus, further disclosed herein are deuterated compounds or salts of Formula (I), in which one or more isotopes of hydrogen have been replaced with deuterium.
[0041] The compounds of the disclosure are defined herein by their chemical structures and/or chemical
names. Where a compound is referred to by both a chemical structure and a chemical name, and the chemical structure and chemical name conflict, the chemical structure is determinative of the compound's identity.
[0042] As used herein, “alkyl” refers to straight chained and branched saturated hydrocarbon groups containing one to thirty carbon atoms, for example, one to six carbon atoms (e.g., 1, 2, 3, 4, 5, or 6). The term Cn means the alkyl group has “n” carbon atoms. For example, C3 alkyl refers to an alkyl group that has 3 carbon atoms. C1-6alkyl refers to an alkyl group having a number of carbon atoms encompassing the entire range (I .e. , 1 to 6 carbon atoms), as well as all subgroups (e.g., 1-2, 1-3, 1-4, 1-5, 1-6, 2-3, 2-4, 2-5, 2-6, 3-4, 3-5, 3-6, 4-5, 4- 6, 5-6, 1, 2, 3, 4, 5, and 6 carbon atoms). Nonlimiting examples of alkyl groups include, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl (2-methylpropyl), and -butyl (1, 1 -dimethylethyl) Unless otherwise indicated, an alkyl group can be an unsubstituted alkyl group or a substituted alkyl group.
[0043] As used herein, “alkylene” refers to a bivalent saturated aliphatic radical. The term Cn means the alkylene group has "n" carbon atoms. For example, Chalky lene refers to an alkylene group having a number of carbon atoms encompassing the entire range, as well as all subgroups, as previously described for "alkyl" groups
[0044] As used herein, the term “haloalkyl” refers to an alkyl group in which one or more of the hydrogen atoms are replaced by halogen. Such groups include but are not limited to, chloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1 ,1 -difluoroethyl, 2-fluoroethyl, 1 -chloro-2-fluoromethyl and 2-fluoroisobutyl. A haloalkyl may be further substituted or unsubstituted, and some cases relate to a haloalkyl having e.g., 1 to 6 carbon atoms, such as C1-6 haloalkyl.
[0045] As used herein, the term “hydroxyalkyl” refers to an alkyl group in which one or more of the hydrogen atoms are replaced by a hydroxyl group (OH). Such groups include but are not limited to, hydroxymethyl, hydroxyethyl, and the like. A hydroxyalkyl may be further substituted or unsubstituted, and some cases relate to a hydroxyalkyl having e.g., 1 to 6 carbon atoms, such as Ci_6 hydroxyalkyl.
[0046] As used herein, the term “cycloalkyl” refers to an aliphatic cyclic hydrocarbon group containing three to eight carbon atoms (e.g., 3, 4, 5, 6, 7, or 8 carbon atoms). The term Cn means the cycloalkyl group has “n" carbon atoms. For example, C5 cycloalkyl refers to a cycloalkyl group that has 5 carbon atoms in the ring. CB-CB cycloalkyl refers to cycloalkyl groups having a number of carbon atoms encompassing the entire range (e.g., 3 to 8 carbon atoms), as well as all subgroups (e.g., 3-4, 3-5, 3-6, 3-7, 3-8, 4-5, 4-6, 4-7, 4-8, 5-6, 5-7, 5-8, 6-7, 6-8, 7-8, 3, 4, 5, 6, 7, and 8 carbon atoms). Nonlimiting examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The cycloalkyl groups described herein can be isolated or fused to another cycloalkyl group, a heterocycloalkyl group, an aryl group and/or a heteroaryl group. When a cycloalkyl group is fused to another cycloalkyl group, then each of the cycloalkyl groups can contain three to eight carbon atoms unless specified otherwise. Unless otherwise indicated, a cycloalkyl group can be unsubstituted or substituted.
[0047] The term “heterocydyl” as used herein refers to a non-aromatic monocyclic, fused, spiro or bridged ring
system which can be saturated or contain one or more units of unsaturation, having 4 to 12 total ring atoms in which 1-3 (e.g., one to three, or one, two, or three) ring atoms is a heteroatom selected from, N, S, and 0. In cases where the heterocyclyl is spiro, the group can comprise, e.g., a 4-membered ring and spiro 5-membered ring; a 4-membered ring and spiro 6-membered ring; a 4-membered ring and spiro 7-membered ring; a 5- membered ring and spiro 6-membered ring; a 5-membered ring and spiro 7-membered ring; a 6-membered ring and spiro 6-membered ring; a 6-membered ring and spiro 7-membered ring; or a 7-membered ring and spiro 7- membered ring; and each ring of the spiro system may contain at least one ring heteroatom, or only one ring may contain at least one ring heteroatom and the other ring can be carbocyclic. In some cases, the heterocyclyl comprises 5-6 ring members. In some cases, the heterocyclyl comprises 5 ring members. In some cases, the heterocyclyl comprises 6 ring members. Examples of heterocyclyl groups include, but are not limited to, oxetanyl, azetidinyl, piperidinyl, piperazinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, azepanyl, diazepanyl, triazepanyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, oxazepanyl, thiazepanyl, tetrahydrofuranyl, tetrahydrothiophenyl, morpholino (including, for example, 3-morpholino, 4-morpholino), 2-thiomorpholino, 3- thiomorpholino, 4-thiomorpholino, 1 -pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, pyrrolidin-2-one, 1- tetrahydropiperazinyl, 2-tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1 -piperidinyl, 2-piperidinyl, 3-piperidinyl, 1- pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, 1 -piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2- thiazolidinyl, 3-thiazolidinyl, 4-thiazolidinyl, 1 -imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 5-imidazolidinyl, and 1,3-dihydro-imidazol-2-onyl. In some cases, heterocyclyl is oxetanyl, azetidinyl, diazepanyl (such as 1 ,4- diazepanyl), azepanyl, piperidinyl (such as 1 -piperidinyl, 2-piperidinyl, 3-piperidinyl, or 4-piperidinyl), or pyrrolidinyl (such as 1 -pyrrolidinyl, 2-pyrrolidinyl, or 3-pyrrolidinyl). In some cases, heterocyclyl is oxetanyl, azetidinyl, diazepanyl or azepanyl. In some cases, heterocyclyl is diazepanyl or azepanyl. In some cases, heterocyclyl is 1 ,4-diazepanyl or azepanyl. In some cases, heterocyclyl is 1 ,4-diazepanyl. In some cases, heterocyclyl is azepanyl. A heterocyclyl ring is unsubstituted or substituted as described herein.
[0048] As used herein, the term "aryl” refers to a monocyclic or bicyclic aromatic group, having 6 to 10 ring atoms. Unless otherwise indicated, an aryl group can be unsubstituted or substituted. Aryl groups can be isolated (e.g., phenyl) or fused to another aryl group (e.g., naphthyl, or anthracenyl) or cyclic group (e.g., indene, dihydroindene).
[0049] As used herein, the term "heteroaryl” refers to a heterocycyl group that is aromatic, having five to twelve total ring atoms (e.g., a monocyclic aromatic ring with 5-6 total ring atoms), and containing 1-3 heteroatoms selected from nitrogen, oxygen, and sulfur atom in the aromatic ring. Unless otherwise indicated, a heteroaryl group can be unsubstituted or substituted. Heteroaryl groups can be isolated (e.g., pyridyl) or fused to another heteroaryl group (e.g., purinyl), a cycloalkyl group (e.g., tetrahydroquinolinyl), a non-aromatic heterocyclyl group (e.g., dihydronaphthyridinyl), and/or an aryl group (e.g., benzothiazolyl and quinolyl). Examples of heteroaryl groups include, but are not limited to, pyrazolyl, thienyl, furyl, pyridyl, pyrrolyl, oxazolyl, quinolyl, thiophenyl, isoquinolyl, indolyl, triazinyl, triazolyl, isothiazolyl, isoxazolyl, imidazolyl, benzothiazolyl,
pyrazinyl, pyrimidinyl, thiazolyl, and thiadiazolyl. When a heteroaryl group is fused to another heteroaryl group, then each ring can contain five or six total ring atoms and one to three heteroatoms in its aromatic ring.
[0050] As used herein, the term "alkoxy” as used herein refers to a O-alkyl” group. The alkoxy group can be unsubstituted or substituted.
[0051] As used herein, the term “haloalkoxy” as used herein refers to a O-haloalkyl” group. The haloalkoxy group can be unsubstituted or substituted.
[0052] As used herein, the term “halo” refers to a fluoro (F), chloro (Cl), bromo (Br), or iodo (I) group.
[0053] A “substituted” functional group (e.g., a substituted heterocyclyl, aryl, or heteroaryl refers to an alkyl, heterocycly I, aryl, or heteroaryl) is a functional, group having at least one hydrogen radical that is substituted with a non-hydrogen radical (i.e., a substituent). Examples of non-hydrogen radicals (or substituents) include, but are not limited to, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, ether, aryl, heteroaryl, heterocycloalkyl, hydroxyl, oxy (or oxo), alkoxyl, ester, thioester, acyl, carboxyl, cyano, nitro, amino, sulfhydryl, and halo. When a substituted alkyl group includes more than one non-hydrogen radical, the substituents can be bound to the same carbon or two or more different carbon atoms. Other substitutions are discussed in relation to specific functional groups or moieties herein.
Pharmaceutically Acceptable Salts
[0054] The compounds described herein can exist in free form, or where appropriate, as salts. Those salts that are pharmaceutically acceptable are of particular interest since they are useful in administering the compounds described herein for medical purposes. Salts that are not pharmaceutically acceptable are useful in manufacturing processes, for isolation and purification purposes, and in some cases, for use in separating stereoisomeric forms of the compounds of the disclosure or intermediates thereof.
[0055] As used herein, the term "pharmaceutically acceptable salt" refers to salts of a compound which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue side effects, such as, toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
[0056] Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al , describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds described herein include those derived from suitable inorganic and organic acids and bases. These salts can be prepared in situ during the final isolation and purification of the compounds.
[0057] Where the compound described herein contains a basic group, or a sufficiently basic bioisostere, acid addition salts can be prepared by 1) reacting the purified compound in its free-base form with a suitable organic or inorganic acid and 2) isolating the salt thus formed. In practice, acid addition salts might be a more convenient form for use and use of the salt amounts to use of the free basic form.
[0058] Examples of pharmaceutically acceptable, non-toxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, glycolate, gluconate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, palmoate, pectinate, persulfate, 3- phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.
[0059] Where the compound described herein contains a carboxyl group or a sufficiently acidic bioisostere, base addition salts can be prepared by 1) reacting the purified compound in its acid form with a suitable organic or inorganic base and 2) isolating the salt thus formed. In practice, use of the base addition salt might be more convenient and use of the salt form inherently amounts to use of the free acid form. Salts derived from appropriate bases include alkali metal (e.g., sodium, lithium, and potassium), alkaline earth metal (e.g., magnesium and calcium), ammonium and N+(Ci-4alkyl)4 salts. This disclosure also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
[0060] Basic addition salts include pharmaceutically acceptable metal and amine salts. Suitable metal salts include the sodium, potassium, calcium, barium, zinc, magnesium, and aluminum. The sodium and potassium salts are usually preferred. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate. Suitable inorganic base addition salts are prepared from metal bases which include sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide and the like. Suitable amine base addition salts are prepared from amines which are frequently used in medicinal chemistry because of their low toxicity and acceptability for medical use. Ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline, N, N'-dibenzylethylenediamine, chloroprocaine, dietanolamine, procaine, N- benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, triethylamine, dibenzylamine, ephenamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino acids, dicyclohexylamine and the like.
[0061] Other acids and bases, although not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds described herein and their pharmaceutically acceptable acid or base addition salts.
[0062] It should be understood that a compound disclosed herein can be present as a mixture/combination of different pharmaceutically acceptable salts. Also contemplated are mixtures/combinations of compounds in free form and pharmaceutically acceptable salts.
Pharmaceutical Formulations
[0063] Also provided herein are pharmaceutical formulations that include an effective amount of compounds of the disclosure and one or more pharmaceutically acceptable excipients. As used herein, the term ‘‘formulation” is used interchangeable with “composition.”
[0064] An "effective amount" includes a "therapeutically effective amount" and a "prophylactically effective amount." The term "therapeutically effective amount" refers to an amount effective in treating and/or ameliorating a disease or condition in a subject. The term "prophylactically effective amount" refers to an amount effective in preventing and/or substantially lessening the chances of a disease or condition in a subject. As used herein, the terms “patient” and “subject” may be used interchangeably and mean animals, such as dogs, cats, cows, horses, and sheep (i.e., non-human animals) and humans. Particular patients or subjects are mammals (e.g., humans). The terms “patient” and “subject” include males and females.
[0065] As used herein, the term “excipient” means any pharmaceutically acceptable additive, carrier, diluent, adjuvant, or other ingredient, other than the active pharmaceutical ingredient (API), suitably selected with respect to the intended form of administration, and consistent with conventional pharmaceutical practices.
[0066] The compounds of the disclosure can be administered alone or as part of a pharmaceutically acceptable composition or formulation. In addition, the compounds can be administered all at once, as for example, by a bolus injection, multiple times, e.g. by a series of tablets, or delivered substantially uniformly over a period of time, as for example, using transdermal delivery. It is also noted that the dose of the compound can be varied over time.
[0067] The compounds disclosed herein and other pharmaceutically active compounds, if desired, can be administered to a subject or patient by any suitable route, e.g. orally, topically, rectally, parenterally, (for example, subcutaneous injections, intravenous, intramuscular, intrasternal, and intrathecal injection or infusion techniques), or as a buccal, inhalation, or nasal spray. The administration can be to provide a systemic effect (e.g. enteral or parenteral). All methods that can be used by those skilled in the art to administer a pharmaceutically active agent are contemplated. In some cases, the disclosed formulations can be administered orally or topically.
[0068] Suitable oral compositions or formulations in accordance with the disclosure include without limitation tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft
capsules, syrups or elixirs. Compositions or formulations suitable for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions.
[0069] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[0070] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
[0071] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
[0072] The active compounds can also be in microencapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least
one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
[0073] The pharmaceutical compositions and formulations described herein may also be administered topically or transdermally, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract Suitable topical formulations are readily prepared for each of these areas or organs. Topical application for the lower intestinal tract, e.g., can be effected in a rectal suppository formulation or in a suitable enema formulation. Dosage forms for topical or transdermal administration of a compound described herein include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, suppositories, or patches.
[0074] For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment, cream, lotion, or gel, containing the active component suspended or dissolved in one or more carriers, and any needed preservatives or buffers as may be required. Carriers for topical administration of the compounds of this disclosure include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2 octyldodecanol, benzyl alcohol and water.
[0075] Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this disclosure. Additionally, the present disclosure contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
[0076] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1 ,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this
purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
[0077] The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0078] In order to prolong the effect of a compound described herein, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
[0079] Compositions for rectal or vaginal administration are specifically suppositories which can be prepared by mixing the compounds described herein with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
[0080] Sterile injectable forms of the compositions described herein may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1 ,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
[0081] The pharmaceutical compositions may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
[0082] The compounds for use in the methods of the disclosure can be formulated in unit dosage form. The term "unit dosage form" refers to physically discrete units suitable as unitary dosage for subjects undergoing treatment, with each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, optionally in association with a suitable pharmaceutical carrier. The unit dosage form can be for a single daily dose or one of multiple daily doses (e.g., about 1 to 4 or more times per day) When multiple daily doses are used, the unit dosage form can be the same or different for each dose.
[0083] The compounds of the disclosure can be administered to a subject or patient at dosage levels in the range of about 0.1 to about 3,000 mg per day. For a normal adult human having a body weight of about 70 kg, a dosage in the range of about 0.01 to about 100 mg per kilogram body weight is typically sufficient The specific dosage and dosage range that will be used can potentially depend on a number of factors, including the requirements of the subject or patient, the severity of the condition or disease being treated, and the pharmacological activity of the compound being administered. The determination of dosage ranges and optimal dosages for a particular subject or patient is within the ordinary skill in the art.
Methods of Treatment
[0084] The compounds disclosed herein (e.g., the compounds of Formula (I), Table 1, and salts thereof) can modulate the aryl hydrocarbon receptor (AHR) pathway, e.g., by modulating AHR in a cell. AHR is a ligand- activated transcription factor that has been implicated in a variety of conditions, including by modulating the immune system during steady state and during infection and inflammation. The AHR pathway has been recognized for its role in the pathogenesis of diseases and disorders including cancer and viral infections.
[0085] Thus, the disclosure provides a method of modulating the aryl hydrocarbon receptor (AHR) in a cell comprising contacting the cell with a therapeutically effective amount of a compound or salt disclosed herein (such as a compound of Formula (I), Table 1, and salts thereof), or a formulation thereof, in an amount effective to modulate the AHR. In some cases, the contacting occurs in vitro. In some cases, the contacting occurs in vivo. In some cases, the contacting comprises administering to a subject in need thereof. As used herein, the terms “patient” and “subject” may be used interchangeably and mean animals, such as dogs, cats, cows, horses, and sheep (i.e., non-human animals) and humans. Particular patients are mammals (e.g., humans). In some cases, the subject suffers from a disease or disorder, e g., cancer or a viral infection
[0086] Another aspect of the disclosure provides a method of treating a disease or disorder in a subject, comprising administering to the subject a therapeutically effective amount of a compound or salt disclosed herein (such as a compound of Formula (I), Table 1, and salts thereof), or a composition thereof. In some cases, the terms “treating”, “treat” or “treatment” and the like can include preventative (e.g., prophylactic) and palliative
treatment. In some cases, the disease or disorder is cancer or a viral infection.
[0087] In some cases, the disease or disorder is cancer. In some cases, a cancer to be treated using the compounds and methods described herein include, but are not limited to, a hematological cancer, a lymphoma, a myeloma, a leukemia, a neurological cancer, skin cancer, breast cancer, a prostate cancer, a cancer of the respiratory tract, a cancer of the reproductive organs, a cancer of the digestive tract, a colorectal cancer, lung cancer, head and neck cancer, a gastrointestinal cancer, a liver cancer, a pancreatic cancer, a genitourinary cancer, a bone cancer, renal cancer, and a vascular cancer. In some cases, the cancer is cancer is a liquid or solid tumor, hematological cancer, lymphoma, myeloma, leukemia, sarcoma, eye cancer, thyroid cancer, parathyroid cancer, neurological cancer, skin cancer, breast cancer, endocrine, uterine cancer, endometrial cancer, prostate cancer, colorectal cancer, lung cancer, head and neck cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, genitourinary cancer, bone cancer, renal cancer, or vascular cancer. In some cases, the cancer is bone cancer. Contemplated bone cancers include, but are not limited to, Histiocytoma of Bone. In some cases, the cancer is endocrine cancer. Contemplated endocrine cancers include but are not limited to Multiple Endocrine Neoplasia Syndrome, adrenal cancer (such as without limitation adrenocortical cancer, adrenocortical carcinoma, or adrenocortical adenoma), thyroid cancer (such as without limitation anaplastic thyroid cancer), and parathyroid cancer. In some cases, the cancer is breast cancer. Contemplated breast cancers include, but are not limited to, triple negative breast cancer, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, and lobular carcinoma in situ. In some cases, the cancer is a cancer of the respiratory tract. Contemplated cancers of the respiratory tract include, but are not limited to, bronchogenic carcinoma, lung carcinoma (such as without limitation small-cell and non-small-cell lung carcinoma), as well as bronchial adenoma and pleuropulmonary blastoma. In some cases, the cancer is central nervous system cancer. Contemplated central nervous system cancers include, but are not limited to, spinal axis tumors, neurofibromatosis-1 associated malignant peripheral nerve sheath tumors (MPNST), and brain cancer. In some cases, the cancer is brain cancer. Contemplated brain cancers include, but are not limited to, glioma, low-grade glioma, astrocytoma (e.g. Grade I — Pilocytic Astrocytoma, Grade II — Low-grade Astrocytoma, Grade III — Anaplastic Astrocytoma, or Grade IV — Glioblastoma (GBM)), glioblastoma multiforme (GBM, also known as glioblastoma), medulloblastoma, craniopharyngioma, ependymoma, Pineal Parenchymal Tumors of Intermediate Differentiation, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, Esthesioneuroblastoma, or retinoblastoma, medullary carcinoma, brain stem and hypophtalmic glioma, cerebellar and cerebral astrocytoma, as well as neuroectodermal and pineal tumor, chordoma, mixed glioma, optic nerve glioma, subependymoma, metastatic brain tumor, pituitary tumors, pituitary adenoma, primitive neuroectodermal (PNET) tumor, or schwannoma. In some cases, the cancer is a type found more commonly in children than adults, such as brain stem glioma, juvenile pilocytic astrocytoma, optic nerve glioma, pineal tumor, primitive neuroectodermal tumors (PNET), or rhabdoid tumor. In some cases, the patient is an adult human. In some cases, the patient is a child or pediatric patient. In some cases, the cancer is a cancer of the male reproductive organs. Contemplated cancers of the male reproductive organs include, but are not limited to,
embryonal carcinoma, seminoma, penile cancer, prostate cancer, and testicular cancer. In some cases, the cancer is a cancer of the female reproductive system. Contemplated cancers of the female reproductive organs include, but are not limited to, ovarian epithelial cancer, fallopian tube cancer, uterine papillary serous carcinoma (UPSC), choriocarcinoma , endometrial, cervical, ovarian, vaginal, and vulvar cancer, as well as sarcoma of the uterus. In some cases, the cancer is an ovarian cancer. Contemplated ovarian cancers include, but are not limited to serous tumor, papillary serous cystadenocarcinoma, endometrioid tumor, mucinous cystadenocarcinoma, granulosa cell tumor, Sertoli-Leydig cell tumor and arrhenoblastoma. In some cases, the cancer is cervical cancer. Contemplated cervical cancers include, but are not limited to squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, neuroendocrine tumor, glassy cell carcinoma and villoglandular adenocarcinoma. In some cases, the cancer is a cancer of the digestive tract. Contemplated cancers of the digestive tract include, but are not limited to, anal, colon, colon carcinoma, colorectal, esophageal, stomach, gallbladder, gastrointestinal, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumors (GIST), duodenal, gastric, pancreatic, rectal, small-intestine, and salivary gland cancers. In some cases, the cancer is esophageal cancer. Contemplated esophageal cancer include, but are not limited to esophageal cell carcinomas and adenocarcinomas, as well as squamous cell carcinomas, leiomyosarcoma, malignant melanoma, rhabdomyosarcoma and lymphoma. In some cases, the cancer is gastric cancer. Contemplated gastric cancers include, but are not limited to intestinal type and diffuse type gastric adenocarcinoma. In some cases, the cancer is pancreatic cancer. Contemplated pancreatic cancers include, but are not limited to pancreatic ductal carcinoma, pancreatic adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinomas and pancreatic endocrine tumors. In some cases, the cancer is cancer of the urinary tract. Contemplated cancers of the urinary tract include, but are not limited to, bladder, penile, kidney, renal pelvis, ureter, urethral and human papillary renal cancers. In some cases, the cancer is a kidney cancer. Contemplated kidney cancers include, but are not limited to renal cell carcinoma, carcinoma of the renal pelvis, urothelial cell carcinoma, juxtaglomerular cell tumor (reninoma), angiomyolipoma, renal oncocytoma, Bellini duct carcinoma, clear-cell sarcoma of the kidney, mesoblastic nephroma and Wilms' tumor. In some cases, the cancer is bladder cancer. Contemplated bladder cancers include, but are not limited to bladder carcinoma, transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, sarcoma and small cell carcinoma. In some cases, the cancer is eye cancer. Contemplated eye cancers include, but are not limited to, intraocular melanoma and retinoblastoma. In some cases, the cancer is liver cancer. Contemplated liver cancers include, but are not limited to, cystadenoma, hepatoma, bile duct carcinoma, Extrahepatic Bile Duct Cancer, hepatobilliary (hepatic and billiary duct) cancer, hepatoblastoma, hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), hepatocholangiocarcinoma and mixed hepatocellular cholangiocarcinoma. In some cases, the cancer is skin cancer. Contemplated skin cancers include, but are not limited to, basal cell carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma skin cancer. In some cases, the cancer is head-and-neck cancer. Contemplated head-and-neck cancers include, but are not limited to, squamous cell cancer of the head and neck, laryngeal,
hypopharyngeal, nasopharyngeal, oropharyngeal cancer, salivary gland cancer, lip and oral cavity cancer and squamous cell. In some cases, the cancer is lymphoma. Contemplated lymphomas include, but are not limited to, lymphocytic lymphoma, AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Burkitt lymphoma, Hodgkin's disease, and lymphoma of the central nervous system. In some cases, the cancer is sarcoma. Contemplated sarcomas include, but are not limited to, sarcoma of the soft tissue, fibrosarcoma, neurofibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma. In some cases, the cancer is leukemia. Contemplated leukemias include, but are not limited to, acute leukemia (such as without limitation acute myeloid leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, and acute erythroleukemia), chronic leukemia (such as without limitation chronic myelocytic leukemia and chronic myelogenous leukemia), and hairy cell leukemia.
[0088] Other cancers contemplated for treatment with the compounds of the disclosure (such as a compound of Formula (I), Table 1 , and salts thereof) and methods described herein can be selected from, e.g., urothelial carcinomas, including, but not limited to, bladder cancer and all transitional cell carcinomas; head and neck squamous cell carcinoma; melanoma, including, but not limited to, uveal melanoma; ovarian cancer, including, but not limited to, a serous subtype of ovarian cancer; renal cell carcinoma, including, but not limited to, clear cell renal cell carcinoma subtype; cervical cancer; gastrointestinal/stomach (GIST) cancer, including but not limited to, stomach cancer; non-small cell lung cancer (NSCLC); acute myeloid leukemia (AML); and esophageal cancers. In some cases, the cancer is a urothelial carcinoma. In some cases, the cancer is bladder cancer. In some cases, the cancer is a transitional cell carcinoma. In some cases, the cancer is head and neck squamous cell carcinoma. In some cases, the cancer is a melanoma. In some cases, the cancer is a uveal melanoma. In some cases, the cancer is ovarian cancer. In some cases, the cancer is a serous subtype of ovarian cancer. In some cases, the cancer is renal cell carcinoma. In some cases, the cancer is a clear cell renal cell carcinoma subtype. In some cases, the cancer is cervical cancer. In some cases, the cancer is a gastrointestinal/stomach (GIST) cancer. In some cases, the cancer is a stomach cancer. In some cases, the cancer is non-small cell lung cancer (NSCLC). In some cases, the cancer is advanced and/or metastatic NSCLC. In some cases, the cancer is an esophageal cancer.
[0089] Other contemplated cancers include without limitation polycythemia vera, Waldenstrom's macroglobulinemia, multiple myeloma, heavy chain disease, epithelial carcinoma, Appendix Cancer, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Embryonal Tumors, Bronchial Tumors, Carcinoid Tumor, Carcinoma of Unknown Primary, Central Nervous System Cancer, Childhood Cancers, Chordoma, Chronic Myeloproliferative Disorders, Ductal Carcinoma In Situ (DCIS), Embryonal Tumors, Endometrial Cancer, Ependymoblastoma, , Extracranial Germ Cell Tumor,
Extragonadal Germ Cell Tumor, Eye Cancer, FibrousGerm Cell Tumor, Gestational Trophoblastic Tumor, Heart Cancer, Histiocytosis, Langerhans Cell Cancer, Hypopharyngeal Cancer, Islet Cell Tumors, Langerhans Cell Histiocytosis, Laryngeal Cancer, Lip and Oral Cavity Cancer, Lobular Carcinoma In Situ (LCIS), Macroglobulinemia, Medulloepithelioma, Merkel Cell Carcinoma, Midline Tract Carcinoma Involving NUT Gene, Mouth Cancer, Multiple Endocrine Neoplasia Syndrome, Plasma Cell Neoplasm, Mycosis Fungoides, Myelodysplastic Syndrome, Myelodysplastic/Myeloprol iterative Neoplasm, Myeloma, Chronic Myeloproliferative Disorder, Nasal Cavity Cancer, Paranasal Sinus Cancer, Nasopharyngeal Cancer, Oral Cancer, Oral Cavity Cancer, Lip Cancer, Oropharyngeal Cancer, Papillomatosis, Paraganglioma, Paranasal Sinus Cancer, Nasal Cavity Cancer, Pharyngeal Cancer, Pheochromocytoma, Pineoblastoma, Plasma Cell Neoplasm, Pleuropulmonary Blastoma, Transitional Cell Cancer, Sezary Syndrome, Supratentorial Primitive Neuroectodermal Tumors, Throat Cancer, Thymoma, Thymic Carcinoma, Transitional Cell Gestational Trophoblastic Tumor, Unknown Primary, Unusual Cancer of Childhood, or diffuse large B-cell lymphoma (DLBCL).
[0090] Also provided are methods and compositions for the diagnosis, prognosis and treatment of viral- associated cancers, including human immunodeficiency virus (HIV) associated solid tumors, human papilloma virus (HPV)-16 positive incurable solid tumors, and adult T-cell leukemia, which is caused by human T-cell leukemia virus type I (HTLV-I) and is a highly aggressive form of CD4+ T-cell leukemia characterized by clonal integration of HTLV-I in leukemic cells; as well as virus-associated tumors in gastric cancer, nasopharyngeal carcinoma, cervical cancer, vaginal cancer, vulvar cancer, squamous cell carcinoma of the head and neck, and Merkel cell carcinoma.
[0091] In some cases, the compounds of the disclosure (such as a compound of Formula (I), Table 1, and salts thereof), or a composition thereof are useful for the treatment of a viral infection. In some cases, the viral infection to be treated using the compounds and methods described herein include, but are not limited to, coronavirus infections and flavivirus infections.
In some cases, the viral infection is a coronavirus infection. The term "coronavirus infection" as used herein means a disease caused by an infection with a coronavirus. Coronaviruses are a family of viruses that cause diseases in mammals and birds. Coronaviruses are in the subfamily Orthocoronavirinae in the family Coronaviridae, in the order Nidovirales. There are four main genera of coronaviruses, known as alpha, beta, gamma, and delta. Coronaviruses that affect humans include Human coronavirus 229E (HCoV-229E), Human coronavirus OC43 (HCoV-OC43), Severe acute respiratory syndrome-related coronavirus (SARS-CoV), Human coronavirus NL63 (HCoV-NL63, New Haven coronavirus), Human coronavirus HKU1 , Middle East respiratory syndrome-related coronavirus (MERS-CoV, previously known as novel coronavirus 2012 and HCoV-EMC), and SARS-CoV-2 (also known as 2019-nCoV).
[0092] In humans, coronaviruses cause respiratory infections, including the common cold, which are typically mild, though rarer forms such as SARS, MERS and SARS-CoV-2 (the cause of the 2019-20 COVID-19
outbreak) can be lethal. Symptoms vary in other species: in chickens, they cause an upper respiratory disease, while in cows and pigs coronaviruses cause diarrhea. There are no vaccines or antiviral drugs to prevent or treat human coronavirus infections. The coronaviruses HCoV-229E, -NL63, -OC43, and -HKU1 continually circulate in the human population and cause respiratory infections in adults and children worldwide. Non-limiting examples of coronaviruses include severe acute respiratory syndrome-related coronavirus (SARS), Middle East respiratory syndrome-related coronavirus (MERS), and SARS-CoV-2 virus (also known as 2019-nCoV). Thus, in some cases, the compounds of the disclosure (such as a compound of Formula (I), a compound of Table 1 , and salts thereof), or pharmaceutically acceptable salt thereof can be used to treat SARS, MERS, and COVID-19 (i.e. , SARS-CoV infection, MERS-CoV infection, and SARS-CoV-2 infection, respectively).
[0093] In some cases, the viral infection is a flavivirus infection. The term "flavivirus infection" as used herein means the disease caused by an infection with a flavivirus.
[0094] Flaviviruses are a family of viruses that cause diseases in mammals and insects. Flaviviruses are in the family Flaviviridae, in the order Amarillovirales. Flaviviruses have positive-sense, single-stranded RNA genomes which are non-segmented and around 10-11 kbp in length. In humans, flaviviruses cause hemorrhagic fever, encephalitis, and the birth defect microcephaly Flavivirus infections range from being asymptomatic to causing death There are vaccines or antiviral drugs to prevent or treat some, but not all, human flavivirus infections. Nonlimiting examples of flaviviruses include West Nile virus, dengue virus, tick-borne encephalitis virus, yellow fever virus, Zika virus and several other viruses which may cause encephalitis. Thus, in some cases, the compounds of the disclosure (such as a compound of Formula (I), a compound of Table 1, and salts thereof), or pharmaceutically acceptable salt thereof can be used to treat flavivirus infections, such as West Nile fever, dengue fever, tick-borne encephalitis, yellow fever, and Zika fever (i.e., West Nile virus infection, dengue virus infection, tick-borne encephalitis virus infection, yellow fever virus infection, and Zika virus infection, respectively).
[0095] Another aspect of the disclosure provides the use of a compound or salt disclosed herein (such as a compound of Formula (I), a compound of Table 1, and salts thereof), or a composition comprising a compound or salt disclosed herein (such as a compound of Formula (I), a compound of Table 1, and salts thereof) in the treatment of a disease or disorder (e.g. , cancer or a viral infection).
[0096] Also contemplated is the use of a compound or salt disclosed herein (such as a compound of Formula (I), a compound of Table 1, and salts thereof), or a composition comprising a compound or salt disclosed herein (such as a compound of Formula (I), a compound of Table 1, and salts thereof) in the manufacture of a medicament in the treatment of a disease or disorder (e.g., cancer or a viral infection).
[0097] Use of a compound as disclosed herein (such as a compound of Formula (I), a compound of T able 1 , and salts thereof), or a pharmaceutically acceptable salt thereof to treat a disease or disorder (e.g., cancer or a viral infection) in a subject also is contemplated. Further, the use of a compound as disclosed herein (such as a compound of Formula (I), a compound of Table 1, and salts thereof), or a pharmaceutically acceptable salt
thereof, also is contemplated. Furthermore, use of a compound as disclosed herein (such as a compound of Formula (I), a compound of Table 1 , and salts thereof), or a pharmaceutically acceptable salt in the preparation of a medicament for use in treating the aforementioned conditions also are contemplated
[0098] In some cases, the compound as disclosed herein (such as a compound of Formula (I), a compound of Table 1, and salts thereof), or pharmaceutically acceptable salt thereof, can be administered in combination with another therapeutic agent to treat a disease or disorder, (e.g. , cancer or a viral infection). Thus, in any of the methods disclosed herein, treatment of a disease or disorder (e.g., cancer or a viral infection) includes coadministration of the compound of Formula (I), Table 1 , or a pharmaceutically acceptable salt thereof in combination with another therapeutic agent. In some cases, the therapeutic agent is an immune checkpoint inhibitor. Non-limiting examples of immune checkpoint inhibitors include PD1 or PDL1 antibodies, such as pembrolizumab, nivolumad, cemiplimab, atezolizumab, dostarlimab, durvalumab, or avelumab.
[0099] In jurisdictions that forbid the patenting of methods that are practiced on the human body, the meaning of “administering” of a composition to a human subject or patient shall be restricted to prescribing a controlled substance that a human subject or patient will self-administer by any technique (e g., orally, inhalation, topical application, injection, insertion, etc.) The broadest reasonable interpretation that is consistent with laws or regulations defining patentable subject matter is intended. In jurisdictions that do not forbid the patenting of methods that are practiced on the human body, the “administering" of compositions includes both methods practiced on the human body and also the foregoing activities.
Synthesis of the Compounds of the Disclosure
[00100] The compounds of the disclosure can be synthesized by any method known in the art. For example, the compounds of Formula (I) or Table 1 , and salts thereof, can be synthesized according to Scheme 1 or Scheme 2.
Scheme 1
[00101] In some cases, compounds of Formula (I) having structure c can be synthesized using the procedure shown in Scheme 1 . Coupling of a substituted 3-oxo-2,3-dihydropyridazine-4-carboxylic acid a with an amine compound b produces substituted 3-oxo-2,3-dihydropyridazine-4-amide compounds having structure c.
[00102] Alternatively, compound c can also be made by connecting an Ar2 group to the scaffold as the last step via cross coupling reactions, such as the Suzuki coupling, as shown in Scheme 2.
Scheme 2 organoboronic acid— Ar2 b' coupling
[00103] Optional further derivatization steps produce compounds as described herein, i.e. , compounds of Formula I having structure c or a modified structure c.
[00104] The coupling of compounds a and b and a’ and b’ can be catalyzed or facilitated by appropriate reagents selected based on the precise nature of compounds a and b and a’ and b’. For example, the coupling of carboxylic acid compound a and amine compound b can be carried out using carbodiimide chemistry e.g., by using GDI or DIEA/HATU in an appropriate solvent, e.g., DMF.
[00105] Compounds a and b and a’ and b’ can be purchased commercially or prepared by a variety of methods from commercially-available starting materials. Optional derivatization reactions to transform compounds having structure c into compounds having a modified structure c can be selected based on the nature of the substituent R1 in compound c, and the functionality desired in the modified structure c. For example, when compound c has a primary amine group on R1, the terminal amine functionality can be further derivatized by methods known in the art to form a variety of functional groups. For example, the amine moiety can be acylated with e.g., an acid chloride or other appropriate reagent.
[00106] Also disclosed herein are compounds useful as synthetic intermediates in the synthesis of the AHR modulators disclosed herein. For example, provided herein are compounds of formula (A) or (B):
wherein Ar1, R3, R1 and RN are as defined above, X is a leaving group, and R is H, C^alkyl, or phenyl. As used herein, a leaving group is a functional group that is compatible with aryl coupling, e.g., a Suzuki coupling, such as halo (e.g., chloro), alkylsulfonyloxy or arylsulfonyloxy (e.g., methanesulfonyloxy, ethanesulfonyloxy, benzenesulfonyloxy, tosyloxy, triflyl). In some cases, X is chloro, fluoro, mesyl, tosyl, or triflyl. Compounds of Formula A or B can react with an Ar2 precursor under suitable coupling conditions (e.g., in the presence of a coupling catalyst), to couple Ar2 to the Compound of Formula A or B, at the “X” position, and thereby form the compound of Formula I. A coupling catalyst can be, e.g., a palladium catalyst (e.g., chloro(crotyl)(tri-tert- butylphosphine)palladium(ll), or Pd(dppf)Cl2). The Ar2 precursor can be a Ar2 boronic acid or boronic ester.
[00107] In some cases, Compound (A) or (B) can be reacted with an amine nucleophile which can then be reacted to form the Ar2 moiety, and further modified as necessary (e.g., to insert the -NRNR1 moiety), to form the compound of Formula (I).
EXAMPLES
[00108] The following examples are provided for illustration and are not intended to limit the scope of the invention.
[00109] Example 1 : Analog Preparation Scheme A
[00110] A solution of 3,6-dichloropyridazine-4-carboxylic acid (15.0 g, 0.078 mol) in AcOH (150 ml) was heated to 120 °C and stirred for 4 hours. After cooling, the reaction mixture was poured into water (300 ml) and a solid was precipitated, filtered, washed with water, and dried to afford compound A. LCMS (ESI) calcd for C5H3CIN2O3 [M+H] + ms/z = 175.1 , found 175.1.
[00111] To a solution of 6-chloro-3-oxo-2,3-dihydropyridazine-4-carboxylic acid (174 mg, 1.0 mmol) in DMF (1.0 ml) was added DIEA (387 mg, 3.0 mmol) and HATU (760 g, 2.0 mmol). After 10 min, the corresponding amine (1.2 mmol) was added. The reaction mixture was stirred at 25°C for 2 h. The LCMS showed the desired MS was detected. The solvent was removed under vacuum and the residue was extracted with EtOAc (20 mL). The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated to yield the desired product which was purified by flash chromatography to yield the corresponding amide.
[00112] A solution of obtained amide compound (1.0 mmol), 2-(3-fluorophenyl)-4,4,5,5-tetramethyl-1 ,3,2- dioxaborolane (266.0 mg, 1.2 mmol), DIEA (154.8 mg, 1.2 mmol), pyridine (2.0 mmol) and Cu(OAc)2 (218 mg, 1.3 mmol) in ACN (2.0 ml) was stirred for 16 h at 25°C. The solvent was removed under vacuum and the residue was extracted with EtOAc (20 mL). The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated to yield the desired product, which was then purified by flash chromatography (eluting with DCM/MeOH from 100:0 to 90:10 in 30 min) to afford intermediate B.
[00113] To a solution of intermediate B (0.2 mmol) in 1 ,4-dioxane / H2O (2 mL/0.2 mL) was added 2-(4- chlorophenyl)-4,4,5,5-tetramethyl-1 ,3,2-dioxaborolane (0.24 mmol), Pd(dppf)Cl2 (0.02 mmol) and K2CO3 (0.4 mmol). The reaction mixture was stirred at 100°C for 16 h under nitrogen. The LCMS showed the desired MS was detected. The solvent was removed under vacuum. The residue was purified by flash chromatography (eluting with DCM/MeOH from 100: 0 to 90:10 in 30 min) to afford the desired product, which was purified by
prep-HPLC (columns: Gemini 5 pm C18 150 x 21.2 mm, mobile phase: MeCN-H2O (0.1% FA), gradient: 50-95, 6.5 min) to afford final analogs.
[00114] Example 2. Analog Preparation Scheme B
[00115] A solution of corresponding amide (1.0 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2- yl) pyrazole (1 2 mmol), DIEA (154.8 mg, 1.2 mmol), pyridine (2.0 mmol) and Cu(OAc)2 (218 mg, 1.3 mmol) in ACN (2.0 ml) was stirred for 16 h at 25°C. The solvent was removed under vacuum and the residue was extracted with EtOAc (20 mL). The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated to get the desired product which was purified by flash chromatography (eluting with DCM/MeOH from 100:0 to 90: 10 in 30 min) to afford intermediate C.
[00116] To a solution of intermediate C (0.2 mmol) in 1,4-dioxane/H2O (2 mL/0.2 mL) was added 2-(4- chlorophenyl)-4,4,5,5-tetramethyl-1 ,3,2-dioxaborolane (0.24 mmol), Pd(dppf)Cl2 (0.02 mmol) and K2CO3 (0.4 mmol). The reaction mixture was stirred at 100°C for 16 h under nitrogen. The LCMS showed the desired MS was detected. The solvent was removed under vacuum. The residue was purified by flash chromatography (eluting with DCM/MeOH from 100: 0 to 90:10 in 30 min) to afford the desired product, which was then purified by prep-HPLC (columns: Gemini 5 m C18 150 x 21.2 mm, mobile phase: MeCN-H2O (0.1% FA), gradient: 50-95, 6.5 min) to afford final analogs.
[00117] Example 3. Analog Preparation Scheme C
Intermediate D Compounds 71-100
[00118] To a solution of 6- chloro-3-oxo-2,3-dihydropyridazine-4-carboxylic acid (3.0 g, 0.017 mol) in DMF (20 ml) was added DIEA (6.66 g, 0.052 mol) and HATU (13.1 g, 0.034 mol). After 10 min, (2S)-1 -methoxy propaneamine (1.84 g, 0.021 mol) was added. The reaction mixture was stirred at 25°C for 2 h. The solvent was removed under vacuum and the residue was extracted with EtOAc (20 mL). The organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated to yield the desired product which was purified by flash chromatography (eluting with PE/EtOAc from 100:0 to 50:50 in 30 min) to afford compound B. LCMS (ESI) calcd for C9H 12CI N3O3 [M+H] + ms/z = 246.2, found 246.2.
[00119] A solution of compound B (300.0 mg, 1.22 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan- 2-yl) pyrazole (1.47mmol), DIEA (189.4 mg, 1.47 mmol), pyridine (193.2 mg, 2.44 mmol) and Cu(OAc)2 (277.3 g, 1.53 mmol) in ACN (10 ml) was stirred for 16 h at 25°C. The LCMS showed the desired MS was detected. The solvent was removed under vacuum and the residue was extracted with EtOAc (20 mL). The organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated to yield the desired product which was purified by flash chromatography (eluting with DCM/MeOH from 100:0 to 90:10 in 30 min) to afford intermediate D. LCMS (ESI) calcd for C,3H i6CI N5O3 [M+H] + ms/z = 326.2, found 326.2..
[00120] To a solution of intermediate D (0.2 mmol) in 1 ,4-dioxane/H2O (2 mL/0.2 mL) was added the corresponding borate (0.24 mmol), Pd(dppf)CI2 (0.02 mmol) and K2CO3 (0.4 mmol). The reaction mixture was stirred at 100°C for 16 h under nitrogen. The LCMS showed the desired MS was detected. The solvent was removed under vacuum. The residue was purified by flash chromatography (eluting with DCM/MeOH from 100: 0 to 90: 10 in 30 min) to afford the desired product, which was purified by prep-HPLC (columns: Gemini 5 m C18 150 x 21.2 mm, mobile phase: MeCN-H2O (0.1% FA), gradient: 50-95, 6.5 min) to afford analogs.
[00121] Example 4. Preparation of compound 57
[00122] A solution of compound B (300.0 mg, 1 22 mmol), 4-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1- ([2-(trimethylsilyl)ethoxy]methyl)-1 H-pyrazole (476.7 mg, 1.47mmol), DIEA (189.4 mg, 1 47 mmol), pyridine (193.2 mg, 2.44 mmol) and Cu(OAc)2 (277.3 g, 1.53 mmol) in ACN (10 ml) was stirred for 16 h at 25°C. The solvent was removed under vacuum and the residue was extracted with EtOAc (20 mL). The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated to yield the desired product which was purified by flash chromatography (eluting with DCM/MeOH from 100:0 to 90:10 in 30 min) to afford compound C.
[00123] To a solution of compound C (53.0 mg, 0.2 mmol) in 1,4-dioxane / H2O (2 mL/0.2 mL) was added 2- (4-chlorophenyl)-4,4,5,5-tetramethyl-1 ,3,2-dioxaborolane (57.2 mg, 0.24 mmol), Pd(dppf)Cl2 (0.02 mmol) and K2CO3 (0.4 mmol). The reaction mixture was stirred at 100°C for 16 h under nitrogen. The solvent was removed under vacuum. The residue was purified by flash chromatography (eluting with DCM/MeOH from 100: 0 to 90:10 in 30 min) to yield the desired product was purified by prep-HPLC (columns: Gemini 5 pirn C18 150 x 21.2 mm, mobile phase: MeCN-H2O (0.1% FA), gradient: 50-95, 6.5 min) to afford compound D. LCMS (ESI) calcd for C24H32CIN5O4Si [M+H] + ms/z = 518.2, found 518.2.
[00124] A solution of compound D (40.0 mg, 0.093 mmol) in HCI-dioxane was stirred for 120 h at 25°C. The solvent was removed under vacuum to yield the desired product which was purified by prep-HPLC (columns: Gemini 5 m C18 150 x 21.2 mm, mobile phase: ACN - H2O (0.1% NH3.H2O), gradient: 50-95, 11.25 min) to afford compound 101. LCMS (ESI) calcd for CisHisCINsOs [M+H] + ms/z = 388.0, found 388.0.
[00125] Example 5 - Additional Synthesis Routes
[00126] Method 1 - Compounds 134, 135, 136, 137, 138, 142, 143, 151, 158, 159, 160, 161, 162, 188, 189, and 190
[00127] To a solution of 6-chloro-3-oxopyridazine-4-carboxamide derivatives (0.092 mmol), corresponding diazole or triazole or indole derivatives (0.111 mmol), cesium carbonate (60 0 mg, 0.1842 mmol) and catalytic agent [Copper(l) iodide (17.5 mg, 0.092 mmol) or Pd-PEPPSI-IPentCh-MePy (3.7 mg, 0.0046 mmol)] in dry DMF (3 ml) The reaction mixture was stirred at 100°C for 1-16 h. The LCMS showed the desired MS was detected The reaction mixture was concentrated. The crude product was purified by prep-TLC (PE/EtOAc =1/1) to get crude product which was purified by prep-HPLC (columns: Gemini 5 urn C18 150 x 21.2 mm, mobile phase: ACN - H2O (0.1% FA), gradient: 30 - 95, 11.25 min) to afford desired product.
[00128] Method 2 - Compounds 110, 114, 116, 117, 125, 127, 145
[00129] To a solution of 6-chloro-N-[(2S)-1 -methoxypropan-2-yl]-2-(1 -methylpyrazol-4-yl)-3-oxopyridazine-4- carboxamide (30.0 mg, 0.0880 mmol) in MeCN (3 mL) was added corresponding secondary amine (0.176 mmol) and potassium carbonate (24.3 mg, 0.176 mmol) stirred for 12 h at 100°C. The LCMS showed the desired MS was detected. The reaction mixture was concentrated. The residue was purified by prep-HPLC (columns: Gemini 5 urn C18 150 x 21.2 mm, mobile phase: ACN - H2O (0.1% FA), gradient: 30 - 95, 10.25 min) to afford desired product.
[00130] Method 3 - Compounds 115, 119, 149, 152
[00131] To a solution of 6-chloro-N-[(2S)-1-methoxypropan-2-yl]-2-(1-methylpyrazol-4-yl)-3-oxopyridazine-4- carboxamide (50.0 mg, 0.1535 mmol) in 1 ,4-dioxane/H2O=5: 1 (3 mL) was added borate derivatives (0.1842 mmol), Pd(dppf)Cl2 (11.2 mg, 0.01535 mmol) and K2CO3 (42.4 mg, 0.307 mmol) stirred for 12 h at 100 °C. The LCMS showed the desired MS was detected. The reaction mixture was concentrated. The reaction mixture was filtered out and concentrated. The residue was purified by prep-HPLC (columns: Gemini 5 urn C18 150 x 21.2 mm, mobile phase: ACN - H2O (0.1% FA), gradient: 40 - 95, 11.00 min) to afford desired product.
[00132] Mass spectrometry data for the compounds synthesized herein are presented in Table 2, below. Table 3 shows NMR and mass spectrometry data for compounds synthesized via the above described methods.
Table 2
Table 3
[00133] Example 5 - AHR Antagonist Reporter Assay in Human Cell Line
[00134] The AhR reporter assay was performed following the protocol of the Human Aryl Hydrocarbon Receptor (AhR) Reporter Assay System (INDIGO Bioscience, #l B06001 -32). AhR Reporter Cell was thawed and pre-incubated in Cell Recovery Medium (CRM) for 6 hours. The media was then removed and the cells were incubated with Compound Screening Medium (CSM) supplemented with 200 pM kynurenic acid for 24 hours in the absence (negative control) or presence of increasing concentrations of test compounds (typical dilution: 128pM, 640pM, 3.2nM, 16nM, 80nM, 400nM, 2pM, 10pM in duplicates). For positive inhibition control, cells activated with 200 pM kynurenic acid were incubated in the presence of literature AHR antagonists; alternatively un-activated cells were used as positive inhibition control. Following 24 hours incubation, the media was removed and Luciferase Detection Reagent (LDR) added. The firefly luciferase activity was quantified using a plate reader. Results were normalized by positive and negative controls.
[00135] Example 6 - AHR-regulated CYP1A1 Expression in Human Cell Line
[00136] To evaluate the AHR inhibitory activity of the test compounds, quantitative PCR analysis was used to determine expression level of the AHR-regulated gene CYP1A1 in a human monocytic U937 cell line upon stimulation of 200 pM kynurenic acid (KA) in the absence or presence of AHR inhibitor. U937 cells were seeded at a concentration of 5X105 cells/well in 200 pL of growth medium in 96-well cell culture microplates CYP1 A1 expression was induced with 200 pM KA (positive control) in the absence or presence of the test compounds for 16 hours. Human U937 cells were typically incubated with eight different concentrations of test compounds (typical dilution: 128 pM, 640 pM, 3.2 nM, 16 nM, 80 nM, 400 nM, 2 pM, 10 pM) and analyzed in duplicate on the same cell culture microplate. After stimulation, the media was removed, the cell RNA was isolated using RNeasy Mini Kit (Qiagen, 74104) and reverse-transcribed to cDNA using PrimeScript RT reagent Kit (Perfect Real Time) (TaKaRa, RR037A). Unstimulated cells were used as the negative control. Taqman probes for human CYP1A1 (Hs01054797 g 1 ) and human GAPDH (Hs02786624 _g1 ) were used to analyze fold expression of CYP1A1 of GAPDH.
[00137] Results are shown in Table 4, below.
Table 4
A> 400 nM; B 100 to 400 nM; C <100 nM
Example 7 - Evaluation of Anti-Tumor Activity
[00138] Female BALB/C mouse was inoculated subcutaneously on the right flank with CT26 tumor cells (3 x 105) in 0.1 ml of RPMI 1640 Medium without serum for tumor development Mice were randomized into 4 groups according to body weight on Day 4 after inoculation. The tumor-bearing mice were treated with Vehicle, anti PD-1 antibody (RMP1-14, BioXCell Catalog No. BP0146), a AHR antagonist compound as disclosed herein and a combination therapy of a AHR antagonist compound as disclosed herein and the anti PD-1 (or established treatment). The AHR antagonist compound was dosed orally at for example 10 mg/kg alone or in combination with established treatment for 16 days. When the established treatment was PD-1 antibody, the antibody was administered via intraperitoneal injection at 10mg/kg, twice every week. The result of the tumor growth inhibition using Example 184 as AHR antagonist compound is shown in Figure 1. All treatment groups showed significantly reduced tumor volume compared with Vehicle group, the p values of anti PD-1 antibody group, example 184 group and combination group were <0.0001 , 0.0083, and <0.0001 , respectively. Compared with anti PD-1 antibody group and example 184 group, the combination group resulted in a significantly reduction in tumor volume, with p values of 0.0235 and <0.0001 , respectively.
[00139] The synergistic tumor growth inhibition of example 184 and anti-PD-1 antibody also translated into significant survival benefit as shown in the survival curve of Figure 2, with p values of 0.0049 against vehicle and 0.001 1 against example 184 standalone group.
[00140] It should be appreciated that all combinations of the foregoing concepts and implementations and additional concepts and implementations discussed in greater detail below are contemplated as being part of the inventive subject matter disclosed herein, and may be employed in any suitable combination to achieve the benefits as described here. In particular, all combinations of claimed subject matter appearing at the end of this
disclosure are contemplated as being part of the inventive subject matter disclosed herein. The foregoing description is given for clearness of understanding only, and no unnecessary limitations should be understood therefrom, as modifications within the scope of the disclosure may be apparent to those having ordinary skill in the art.
[00141] The terms “substantially” and “about” used throughout this Specification are used to describe and account for small fluctuations. For example, they can refer to less than or equal to ±5%, such as less than or equal to ±2%, such as less than or equal to ±1%, such as less than or equal to ±0.5%, such as less than or equal to ±0.2%, such as less than or equal to ±0.1%, such as less than or equal to ±0.05%.
[00142] Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise” and variations such as “comprises” and “comprising” will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
[00143] Throughout the specification, where compositions are described as including components or materials, it is contemplated that the compositions can also consist essentially of, or consist of, any combination of the recited components or materials, unless described otherwise. Likewise, where methods are described as including particular steps, it is contemplated that the methods can also consist essentially of, or consist of, any combination of the recited steps, unless described otherwise. The disclosure illustratively disclosed herein suitably may be practiced in the absence of any element or step which is not specifically disclosed herein.
[00144] The practice of a method disclosed herein, and individual steps thereof, can be performed manually and/or with the aid of or automation provided by electronic equipment. Although processes have been described with reference to particular implementations, a person of ordinary skill in the art will readily appreciate that other ways of performing the acts associated with the methods may be used. For example, the order of various steps may be changed without departing from the scope or spirit of the method, unless described otherwise. In addition, some of the individual steps can be combined, omitted, or further subdivided into additional steps.
[00145] All patents, publications and references cited herein are hereby fully incorporated by reference. In case of conflict between the present disclosure and incorporated patents, publications and references, the present disclosure should control.
Claims (1)
- We Claim:1 . A compound, or pharmaceutically acceptable salt thereof, having a structure of Formula (I): wherein each RN is independently H or C^alkyl;R1 is H, C1-6alkyl, C1-6alkylene-NRNRN, C1-6alkylene-O-C^alkyl, C1-6alkylene-C(O)R2, C1-6alkylene-NRN-C(O)-C1-3alkyl, Cs-ecycloalkyl, or 4-12 membered heterocyclyl, wherein 1-3 ring atoms are selected from 0, N, and S, and the cycloalkyl or heterocyclyl is optionally substituted with 1 or 2 Ci ealkyl, C(O)- C1-6alkyl, and =0;R2 is OH, O-Ci.6alkyl, or NRNRN;Ar1 is Ce-waryl or 5-10 membered heteroaryl, wherein 1-3 ring atoms are selected from 0, N, and S, and Ar1 is optionally substituted with 1 or 2 R3; each R3 is independently halo, Ci-salkyl, Ci-shaloalkyl, or Cs-ecycloalkyl;Ar2 is C5-8cycloakly, C5-8cycloalkenyl, C6-10aryl, or 5-12 membered heterocyclyl or heteroaryl, wherein 1- 3 ring atoms are selected from 0, N, and S, and Ar2 is optionally substituted with 1 , 2, or 3 R4; each R4 is independently halo, OH, =0, ON, C1-6alkyl, Ci-shaloalkyl, C1-6hydroxyalkyl, C1-6alkoxy, Ci. ehaloalkoxy, NRNRN, C0NRNRN, COOH, COO-Ci.6alkyl, C(O)-Ci.6alkyl, SO2-C1-6alkyl, C3-8cycloalkyl, 4-12 membered heterocyclyl or 5-12 membered heteroaryl, wherein 1-3 ring atoms are selected from 0, N, and S, or phenyl, and the heterocyclyl, heteroaryl, or phenyl is substituted with 0, 1 , or 2 substituents independently selected from halo and C^alkyl, or R1 can be C^ehydroxyalkyl when Ar2 is (1) C5-8cycloakly, C5-8cycloalkenyl, Cwaryl, 4-12- membered heterocyclyl, or 5- or 7-12 membered heteroaryl and Ar2 is optionally substituted with 1 , 2, or 3 R4; or (2) phenyl or 6-membered heteroaryl and Ar2 is substituted with at least one R4 selected from CONRNRN, COOH, COO-C1-6alkyl, C(O)-C1-6alkyl, SO2-C1-6alkyl, Cs-ecycloalkyl, 4-12 membered heterocyclyl, 5-12 membered heteroaryl, and phenyl, and the phenyl, heterocyclyl or heteroaryl is substituted with 0, 1, or 2 substituents independently selected from halo and C^alkyl.2. The compound or salt of claim 1 , wherein each RN is independently H or methyl.3. The compound or salt of claim 1 or 2, wherein R1 is H or C^alkyl.4. The compound or salt of claim 3, wherein R1 is methyl.5. The compound or salt of claim 1 or 2, wherein R1 is C1-6alkylene-NRNRN or C1-6alkylene-O-Ci. ealkyl.7. The compound or salt of claim 5, wherein R1 isThe compound or salt of claim 7, wherein R1 is9. The compound or salt of claim 1 or 2, wherein R1 is Ci.ealkylene-C(O)R2 orCi.6alkylene-NRN-C(O)CH3.10. The compound or salt of claim 9, wherein R2 is OH.11 . The compound or salt of claim 9, wherein R2 is NH2, NHCH3, or N(CHe)2.12. The compound or salt of claim 9, wherein R1 is14. The compound or salt of claim 1 or 2, wherein R1 is heterocyclyl comprising 4-12 total ring atoms, wherein 1-3 of the ring atoms are selected from 0, N, and S.15. The compound or salt of claim 12, wherein the heterocyclyl is unsubstituted.16. The compound or salt of claim 12, wherein the heterocyclyl is substituted with 1 or 2 Ci-salkyl, C(O)-C1-6alkyl, or =0.70The compound or salt of claim 17, wherein The compound or salt of claim 1 or 2, wherein R1 is C2-6alkylene-C(O)-NRNRN. The compound or salt of claim 1 or 2, wherein R1 is C2-6hydroxyalkyl .A^OH The compound or salt of claim 21 , wherein R1 is = The compound or salt of any one of claims 1 to 22, wherein Ar1 is C6-10aryl. The compound or salt of claim 23, wherein Ar1 is phenyl. The compound or salt of any one of claims 1 to 22, wherein Ar1 is 5-10 membered heteroaryl. The compound or salt of any one of claims 23 to 25, wherein Ar1 is unsubstituted.71 The compound or salt of claim 26, wherein Ar1 is28. The compound or salt of any one of claims 23 to 25, wherein Ar1 is substituted with 1 or 2 R3.29. The compound or salt of claim 28, wherein R3 is fluoro, chloro, methyl, ethyl, isopropyl, or trifluoromethyl.The compound or salt of claim 28 or 29, wherein Ar1 isThe compound or salt of claim 30, wherein Ar1 is \32. The compound or salt of any one of claims 1 to 31 , wherein Ar2 is C6-10ary I.33. The compound or salt of claim 32, wherein Ar2 is phenyl.34. The compound or salt of any one of claims 1 to 31 , wherein Ar2 is 5-12 membered heteroaryl.35. The compound or salt of any one of claims 1 to 31 , wherein Ar2 is C5-8cycloal kyl, C5- scycloalkenyl, or 5-12 membered heterocyclyl.36. The compound or salt of claim 35, wherein Ar2 is 5-12 membered heterocyclyl.37. The compound or salt of claim 32, 34, 35, or 36, wherein Ar2 is unsubstituted.38. The compound or salt of any one of claims 32 to 36, wherein Ar2 is substituted with 1 , 2, or 3The compound or salt of claim 38, wherein Ar2 is substituted with 1 or 2 R4.The compound or salt of claim 38 or 39, wherein at least one R4 is halo.The compound or salt of claim 40, wherein at least one R4 is chloro.The compound or salt of claim 41 , wherein Ar2 is C43. The compound or salt of any one of claims 38 to 41 , wherein at least one R4 is fluoro, chloro, OH, ON, CH3, CH2CH3, CH(CH3)2, C(CH3)3, OCH3, CF3, OCF3, CHF2, CH2F, OCHF2, NH2, N(CH3)2, CONH2, COOH, SO2CH3, cyclopropyl, or morpholino.44. The compound or salt of any one of claims 38 to 41 and 43, wherein at least one R4 selected from CONRNRN, COOH, COO-Ci-3alkyl, C(O)-C1-6alkyl, SOz-C1-6alkyl, C3-8cycloalkyl, 4-12 membered heterocyclyl, 5-12 membered heteroaryl, and phenyl, and the phenyl, heterocyclyl or heteroaryl is substituted with 0, 1, or 2 substituents independently selected from halo and C1-6alkyl.45. The compound or salt of claim 44, wherein Ar2 is phenyl, pyridyl, pyrimidinyl, pyrazolyl, or triazolyl, and at least one R4 is phenyl or halo substituted-phenyl.46. The compound or salt of any one of claims 1 to 31 , wherein Ar2 is49. A compound as listed in T able 1 , or a pharmaceutically acceptable salt thereof.50. A pharmaceutical formulation comprising the compound or salt of any one of claims 1 to 49 and a pharmaceutically acceptable excipient.51 . A method for modulating aryl hydrocarbon receptor (AHR) activity in a subject, comprising contacting the AHR with the compound or salt of any one of claims 1 to 49 or the pharmaceutical composition of claim 50.52. A method for treating or preventing a disease or disorder in a subject, comprising administering to the subject a therapeutically effective amount of the compound or salt of any one of claims 1 to 49 or the pharmaceutical composition of claim 50.53. The method of claim 52, wherein the disease or disorder is cancer, a viral infection, or pulmonary arterial hypertension (PAH).54. The method of claim 53, wherein the viral infection is flavivirus infection or coronavirus infection.55. The method of claim 54, wherein the viral infection is flavivirus infection.56. The method of claim 55, wherein the flavivirus infection is Zika virus infection.57. The method of claim 54, wherein the viral infection is coronavirus infection.58. The method of claim 57, wherein the coronavirus infection is severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), or Coronavirus disease 2019 (COVID-19).59. The method of claim 58, wherein the coronavirus infection is Coronavirus disease 2019 (COVID-19).60. The method of claim 53, wherein the disease or disorder is cancer.61 . The method of claim 60, wherein the cancer is a liquid or solid tumor, hematological cancer, lymphoma, myeloma, leukemia, sarcoma, eye cancer, thyroid cancer, parathyroid cancer, neurological cancer, skin cancer, breast cancer, uterine cancer, endometrial cancer, prostate cancer, colorectal cancer, lung cancer, head and neck cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, genitourinary cancer, bone cancer, renal cancer, or vascular cancer.62. The method of claim 53, wherein the disorder is PAH.63. The method of any one of claims 51 to 62, further comprising administering a therapeutic agent to the subject.64. The method of claim 63, wherein the therapeutic agent is an immune checkpoint inhibitor.65. The method of claim 64, wherein the immune checkpoint is PD1 or PDL1 .66. The method of claim 64 or 65, wherein the immune checkpoint inhibitor is pembrolizumab, nivolumad, cemiplimab, atezolizumab, dostarlimab, durvalumab, avelumab, or a combination thereof.67. Use of the compound or salt of any one of claims 1 to 49 or the pharmaceutical composition of claim 50 for modulating AHR activity in a subject.68. Use of the compound or salt of any one of claims 1 to 49 or the pharmaceutical composition of claim 50 for treating or preventing a disease or disorder in a subject.69. A compound having a structure of Formula (A) or (B) whereinAr1 is Ce-waryl or 5-10 membered heteroaryl, wherein 1-3 ring atoms are selected from 0, N, and S, and Ar1 is optionally substituted with 1 or 2 R3; each R3 is independently halo, C1-6alkyl, C1-6haloalkyl, or Cs-ecycloalkyl;R1 is H, C1-6alkyl, C1-6alkylene-NRNRN, C1-6alkylene-O-C1-6alkyl, C1-6alkylene-C(O)R2, C1-6alkylene-NRN-C(O)-C1-3alkyl, C3-8cycloalkyl, or 4-12 membered heterocyclyl, wherein 1-3 ring atoms are selected from 0, N, and S, and the cycloalkyl or heterocyclyl is optionally substituted with 1 or 2 C1-6alkyl, 0(0)- C1-6alkyl, and =0;R2 is OH, O-Ci.6alkyl, or NRNRN; each RN is independently H or C1-6alkyl;X is a leaving group; and R is H, Ci.6alkyl, C1-6alkylenephenyl, aryl or heteroaryl, and when alkyl, aryl, or heteroaryl, can be optionally substituted.70. The compound of claim 69, wherein X is chloro, fluoro, mesyl, tosyl, or triflyl.71. A method of preparing the compound or salt of Formula (I) of any one of claims 1 to 49, comprising admixing the compound of Formula (B) of claim 69 or 70 with Ar2-boronic acid or Ar2-boronic ester in the presence of a catalyst to form the compound of Formula (I).72. A method of preparing the compound or salt of Formula (I) of any one of claims 1 to 49, comprising admixing the compound of Formula (A) of claim 69 or 70 with Ar2-boronic acid or Ar2-boronic ester in the presence of a catalyst to form an intermediate then converting the -OR moiety of the intermediate to a - N(RN)R1 moiety to form the compound of Formula (I).73. The method of claim 71 or 72, wherein the catalyst comprises a palladium catalyst.74. A method of preparing the compound or salt of Formula (I) of any one of claims 1 to 49, comprising admixing the compound of Formula (B) of claim 69 or 70 with an amine nucleophile, optionally in the presence of a catalyst, to form an aromatic intermediate, then reacting the aromatic intermediate with a reagent to form the compound of Formula (I).75. A method of preparing the compound or salt of Formula (I) of any one of claims 1 to 49, comprising (i) admixing the compound of Formula (A) of claim 69 or 70 with an amine nucleophile, optionally in the presence of a catalyst, to form an aromatic intermediate, (ii) reacting the aromatic intermediate with a reagent to form an ester intermediate, and (iii) converting the -OR moiety of the ester intermediate to a -N(RN)R1 moiety to form the compound of Formula (I).78
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2021/118095 | 2021-09-14 | ||
CN2021118095 | 2021-09-14 | ||
US202163281989P | 2021-11-22 | 2021-11-22 | |
US63/281,989 | 2021-11-22 | ||
CNPCT/CN2022/079169 | 2022-03-04 | ||
CN2022079169 | 2022-03-04 | ||
PCT/US2022/043403 WO2023043753A1 (en) | 2021-09-14 | 2022-09-14 | 2-aryl or heteroaryl-3-oxo-4-carbamide-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in the treatment of diseases and disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2022345008A1 true AU2022345008A1 (en) | 2024-04-04 |
Family
ID=83594161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2022345008A Pending AU2022345008A1 (en) | 2021-09-14 | 2022-09-14 | 2-aryl or heteroaryl-3-oxo-4-carbamide-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in the treatment of diseases and disorders |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2022345008A1 (en) |
TW (1) | TW202320777A (en) |
WO (1) | WO2023043753A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114835687B (en) * | 2021-04-02 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR inhibitors |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3464248B1 (en) * | 2016-05-25 | 2021-09-08 | Bayer Pharma Aktiengesellschaft | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides |
JOP20190193A1 (en) * | 2017-02-09 | 2019-08-08 | Bayer Pharma AG | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer |
WO2019101642A1 (en) * | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides |
US11591311B2 (en) * | 2017-11-21 | 2023-02-28 | Bayer Aktiengesellschaft | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides |
EP3715471A1 (en) * | 2019-03-29 | 2020-09-30 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Ahr signature marker set |
-
2022
- 2022-09-14 TW TW111134778A patent/TW202320777A/en unknown
- 2022-09-14 WO PCT/US2022/043403 patent/WO2023043753A1/en active Application Filing
- 2022-09-14 AU AU2022345008A patent/AU2022345008A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202320777A (en) | 2023-06-01 |
WO2023043753A1 (en) | 2023-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014298051B2 (en) | Novel quinazolinones as bromodomain inhibitors | |
CN107406438B (en) | Inhibitors of bromodomains | |
BR112021002327A2 (en) | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4,5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h) derivatives -one and related compounds as ptpn11(shp2) inhibitors for cancer treatment | |
JP7471232B2 (en) | Small molecule degraders of POLYBROMO-1 (PBRM1) | |
CN107207474A (en) | Substituted heterocycle is used as bromine domain inhibitor | |
CA2966452A1 (en) | Substituted bicyclic compounds as bromodomain inhibitors | |
US7875603B2 (en) | Specific inhibitors for vascular endothelial growth factor receptors | |
WO2007130383A2 (en) | Compositions and treatments using pyridazine compounds and secretases | |
EP1914234A1 (en) | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors | |
WO2009136889A1 (en) | Specific inhibitors for vascular endothelial growth factor receptors | |
CA2966303A1 (en) | Substituted pyridines as bromodomain inhibitors | |
JP5411393B2 (en) | Pyrazoloquinolines | |
EP2084159A1 (en) | Pyrido ý2, 3-d¨pyrimidines and their use as kinase inhibitors | |
US20190192521A1 (en) | Methods of Treating Arid1A-Mutated Cancers With HDAC6 Inhibitors and EZH2 Inhibitors | |
CN103930408A (en) | Morpholinyl benzotriazine for use in cancer therapy | |
WO2008150260A1 (en) | 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents | |
WO2014190758A1 (en) | Conjugate of benzofuranone and indole or azaindole, and preparation and uses thereof | |
WO2013190300A1 (en) | Cyclohexane-1,2'-naphthalene-1',2"-imidazole compounds and their use as bace inhibitors | |
WO2023086428A2 (en) | Novel modulators of the aryl hydrocarbon receptor and methods of use thereof | |
AU2022345008A1 (en) | 2-aryl or heteroaryl-3-oxo-4-carbamide-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in the treatment of diseases and disorders | |
JP2018534243A (en) | Androgen receptor antagonist | |
CA3152306A1 (en) | Selective hdac6 degraders and methods of use thereof | |
CN112237579A (en) | Pharmaceutical composition and use thereof | |
WO2023143147A1 (en) | Pyridazopyridone compounds, pharmaceutical composition thereof and use thereof | |
CN118234710A (en) | 2-Aryl or heteroaryl-3-oxo-4-carboxamide-6-cyclo-dihydropyrazine aryl hydrocarbon receptor modulators and use thereof in the treatment of diseases and conditions |